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Abstract
Recent genetic data can o↵er important insights into the roles of lipoprotein subfractions and particle sizes
in preventing coronary artery disease (CAD), as previous observational studies have often reported conflicting
results. We used the LD score regression to estimate the genetic correlation of 77 subfraction traits with
traditional lipid profile and identified 27 traits that may represent distinct genetic mechanisms. We then used
Mendelian randomization (MR) to estimate the causal e↵ect of these traits on the risk of CAD. In univariable
MR, the concentration and content of medium high-density lipoprotein (HDL) particles showed a protective e↵ect
against CAD. The e↵ect was not attenuated in multivariable analyses. Multivariable MR analyses also found
that small HDL particles and smaller mean HDL particle diameter may have a protective e↵ect. We identified
four genetic markers for HDL particle size and CAD. Further investigations are needed to fully understand the
role of HDL particle size.
1 Introduction
Lipoprotein subfractions have been increasingly studied in epidemiological research and used in clinical practice to
predict the risk of cardiovascular diseases (CVD) [1–3]. Several studies have identified potentially novel subfraction
predictors for CVD [2, 4–8] and demonstrated that the addition of subfraction measurements can significantly
improve the risk prediction for CVD [1, 9–11]. However, these observational studies often provide conflicting
evidence on the precise roles of the lipoprotein subfractions. For example, while some studies suggested that small,
dense low-density lipoprotein (LDL) particles may be more atherogenic [4, 12], others found that larger LDL size
is associated with higher CVD risk [13, 14]. Some recent observational studies found that the inverse association
of CVD outcomes with smaller high-density lipoprotein (HDL) particles is stronger than the association with
larger HDL particles [6, 11, 15, 16], but other studies reached the opposite conclusion in di↵erent cohorts [17, 18].
Currently, the utility of lipoprotein subfractions or particle sizes in routine clinical practice remains controversial
[14, 19–21], as there is still a great uncertainty about their causal roles in CVD, largely due to a lack of intervention
data [21].
Mendelian randomization (MR) is an useful causal inference method that avoids many common pitfalls of
observational cohort studies [22]. By using genetic variation as instrumental variables, MR asks if the genetic
predisposition to a higher level of the exposure (in this case, lipoprotein subfractions) is associated with higher
occurrences of the disease outcome [23]. A positive association suggests a causally protective e↵ect of the exposure
if the genetic variants satisfy the instrumental variable assumptions [23, 24]. Since Mendelian randomization can
provide unbiased causal estimate even when there are unmeasured confounders, it is generally considered more
credible than other non-randomized designs and is quickly gaining popularity in epidemiological research [25, 26].
MR has been used to estimate the e↵ect of several metabolites on CVD, but most prior studies are limited to just
one or a few risk exposures at a time [27, 28].
In this study, we will use recent genetic data to investigate the roles of lipid and lipoprotein traits in the
occurrence of coronary artery disease (CAD) and myocardial infarction (MI). In particular, we are interested in
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Table 1: Information about the GWAS summary datasets used in this article. The columns are the phenotypes re-
ported by the GWAS studies, the consortium or name of the first author of the publication, PubMed ID, population,
sample size, other GWAS datasets with other lapping sample, and URLs we used to download the datasets.
Phenotype Dataset Name PubMed
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discovering lipoprotein subfractions that may be causal risk factors for CAD and MI in addition to the traditional
lipid profile (LDL cholesterol, HDL cholesterol, and triglycerides levels). To this end, we will first estimate the
genetic correlation of the lipoprotein subfractions and particle sizes with the tradition risk factors and remove the
traits that have a high genetic correlation. We will then use MR to estimate the causal e↵ects of the selected
lipoprotein subfractions and particle sizes on CAD and MI. Finally, we will explore potential genetic markers for
the identified lipoprotein and subfraction traits.
2 Materials and Methods
GWAS summary datasets and lipoprotein particle measurements
Table 1 describes all GWAS summary datasets used in this study, including two GWAS of the traditional lipid
risk factors [29, 30], two recent GWAS of the human lipidome [31, 32], and three GWAS of CAD or MI [33–35].
In the two GWAS of the lipidome [31, 32], high-throughput nuclear magnetic resonance (NMR) spectroscopy was
used to measure the circulating lipid and lipoprotein traits [36]. We investigated the 82 lipid and lipoprotein
traits measured in these studies that are related to very-low-density lipoprotein (VLDL), LDL, intermediate-
density lipoprotein (IDL) and HDL subfractions and particle sizes. All the subfraction traits are named with three
components that are separated by hyphens: the first component indicates the size (XS, S, M, L, XL, XXL); the
second component indicates the fraction according to the lipoprotein density (VLDL, LDL, IDL, HDL); the third
component indicates the measurement (C for total cholesterol, CE for cholesterol esters, FC for free cholesterol, L
for total lipids, P for particle concentration, PL for phospholipids, TG for triglycerides). For example, M-HDL-P
refers to the concentration of medium HDL particles.
Aside from the concentration and content of lipoprotein subfractions, the two lipidome GWAS also measured
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the traditional lipid traits (TG, LDL-C, HDL-C), the average diameter of the fractions (VLDL-D, LDL-D, HDL-D)
and the concentration of apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB). A full list of the lipoprotein
measurements investigated in this article can be found in Appendix 1.
Genetic correlation and phenotypic screening
Genetic correlation is a measure of association between the genetic determinants of two phenotypes. It is concep-
tually di↵erent from epidemiological correlation that can be directly estimated from cross-sectional data. In this
study, we applied the LD-score regression [37] to the lipidome GWAS [31, 32] to estimate the genetic correlations
between the lipoprotein subfractions, particle sizes, and traditional risk factors. We then removed lipoprotein sub-
fractions and particle sizes that are strongly correlated with the traditional risk factors, defined as an estimated
genetic correlation ¿ 0.8 with TG, LDL-C, HDL-C, ApoB, or ApoA1 in the GWAS published by Davis et al. [31].
Because these traits are largely co-determined with the traditional risk factors, they do not represent independent
biological mechanisms and may lead to multicollinearity issues in multivariate MR analyses. Finally, we obtained
an independent estimate of the genetic correlations between the selected traits by applying the LD score regression
to the GWAS published by Kettunen et al. [32]. We used Bonferroni’s procedure to correct for multiple testing
(familywise error rate at 0.05).
Three-sample Mendelian randomization design
For Mendelian randomization, we employed a three-sample design [38] in which one GWAS was used to select
independent genetic instruments that are associated with one or several lipoprotein measures. The other two
GWAS were then used to obtain summary associations of the selected SNPs with the exposure and the outcome, as
in a typical two-sample MR design [39, 40]. More specifically, the selection GWAS was used to create a set of SNPs
that are in linkage equilibrium with each other in a reference panel (distance > 10 megabase pairs, r2 < 0.001). This
was done by ordering the SNPs by the p-values of their association with the trait(s) under investigation and then
selecting them greedily using the linkage-disequilibrium (LD) clumping function in the PLINK software package
[41]. To avoid winner’s curse, we require the other two GWAS to have no overlapping sample with the selection
GWAS.
As the GWAS published by Davis et al. [31] has a smaller sample size, we used it to select the genetic instruments
so the larger dataset can be used for statistical estimation. In univariable MR, associations of the selected SNPs
with the exposure trait (a lipoprotein subfraction or a particle size trait) were obtained from the GWAS published
by Kettunen et al. [32] and the associations with MI were obtained using summary data from an interim release of
UK BioBank [35]. To maximize the statistical power, we used the so-called “genome-wide MR” design. Independent
SNPs are selected by using LD clumping, but we do not truncate the list of SNPs by their p-values. More details
about this design can be found in a previous methodological article [38].
To control for potential pleiotropic e↵ects via the traditional risk factors, we performed two multivariable MR
analyses for each lipoprotein subfraction or particle size under investigation. The first multivariable MR analysis
considers four exposures: TG, LDL-C, HDL-C, and the lipoprotein measurement under investigation. The second
multivariable MR analysis replaces LDL-C and HDL-C with ApoB and ApoA1, in accordance with some recent
studies [42]. SNPs were ranked by their minimum p-values with the four exposures and are selected as instruments
only if they were associated with at least one of the four exposures (p-value  10 4). Both multivariable MR
analyses used the Davis [31] and GERA [29] datasets for instrument selection, the Kettunen [32] and GLGC [30]
datasets for the associations of the instruments with the exposures, and the CARDIoGRAMplusC4D + UK Biobank
[34] dataset for the associations with CAD.
Statistical estimation
For univariable MR, we used the robust adjusted profile score (RAPS) because it is more e cient and robust
than many conventional methods [38, 43]. RAPS can consistently estimate the causal e↵ect even when some of
the genetic variants violate instrumental variables assumptions. For multivariable MR, we used an extension to
RAPS called GRAPPLE to obtain the causal e↵ect estimates of multiple exposures [44]. GRAPPLE also allows
the exposure GWAS to have overlapping sample with the outcome GWAS, while the original RAPS does not. We
assessed the strength of the instruments using the modified Cochran’s Q statistic [45]. Because many lipoprotein
subfraction traits were analyzed simultaneously, we used the Benjamini-Hochberg procedure to correct for multiple
testing [46] and the false discovery rate was set to be 0.05. More detail about the statistical methods can be found
in Appendix 3.
3
Genetic markers for lipoprotein subfractions and CAD
To obtain genetic markers, we selected SNPs that are associated with the lipoprotein measurements identified in
the MR (p-value  5 ⇥ 10 8) and CAD (p-value  0.05) but are not associated with LDL-C or ApoB (p-value
  10 3). To maximize the power of this exploratory analysis, we meta-analyzed the results of the two lipidome
GWAS [31, 32] by inverse-variance weighting. For the associations with LDL-C and CAD, we used the GWAS
summary data reported by the GLGC [30] and CARDIoGRAMplusC4D [34] consortia. We used LD clumping to
obtain independent markers [41] and then validate the markers using tissue-specific gene expression data from the
GTEx project.
Sensitivity analysis and replicability
Because we had multiple GWAS summary datasets for the lipoprotein subfractions and CAD/MI (Table 1), we
swapped the roles of the GWAS datasets in the three-sample MR design whenever permitted by the statistical
methods to obtain multiple statistical estimates. These estimates are not completely independent of the primary
results, but they can nonetheless be used to assess replicability. As a sensitivity analysis, We further analyzed
univariable MR using inverse-variance weighting (IVW) [47] and weighted median [48] and compared with the
primary results obtained by RAPS. We also assessed the assumptions made by RAPS using some diagnostic plots
suggested in previous methodological articles [38].
3 Results
Genetic correlations and phenotypic screening
We obtained the genetic correlations of the lipoprotein subfractions and particle sizes with the traditional lipid risk
factors: TG, LDL-C, HDL-C, ApoB, and ApoA1 (Table 1). We found that almost all VLDL subfractions traits
(besides those related to very small VLDL subfraction) and the mean VLDL particle diameter have an estimated
genetic correlation with TG very close to 1. Most traits related to the large and very large HDL subfractions also
have a high genetic correlation with HDL-C and ApoA1.
After removing traits that are strongly correlated with the traditional risk factors, we obtained 27 traits that
may involve independent genetic mechanisms. Figure 1 shows the genetic correlation matrix for these traits and
the traditional lipid factors. The selected traits can be divided into two groups based on whether they are related
to VLDL/LDL/IDL particles or HDL particles. Within each group, most traits were strongly correlated with the
others. In the first group, most traits had a positive genetic correlation with LDL-C and ApoB, while in the
second group, most traits had a positive genetic correlation with HDL-C and ApoA1. Exceptions include LDL-D,
which had a negative but statistically non-significant genetic correlation with LDL-C and ApoB, and S-HDL-P and
S-HDL-L, which showed no or weak genetic correlation with HDL-C and ApoA1.
Mendelian randomization
Figure 2 shows the estimated causal e↵ect of the selected lipoprotein measurements on MI or CAD that are
statistically significant (false discovery rate = 0.05). The unfiltered results can be found in Appendix 3, which also
contains results of the sensitivity and replicability analyses.
The concentration and lipid content of VLDL, LDL, and IDL subfractions showed harmful and nearly uniform
e↵ects on MI in univariable MR. However, after adjusting for the traditional lipid risk factors, the e↵ects of these
ApoB-related subfractions become close to zero (besides IDL-FC in one multivariable analysis). The mean diameter
of LDL particles (LDL-D) showed a harmful e↵ect on MI in univariable MR, though the e↵ect was smaller than
those of the LDL subfractions in univariable MR. The estimated e↵ect of LDL-D was attenuated in the multivariable
MR analyses.
The concentration and content of medium HDL particles showed protective e↵ects in univariable and multivari-
able MR analyses. In particular, adjusting for the traditional lipid risk factors did not attenuate the e↵ect of traits
related to medium HDL. The concentration of and total lipid in small HDL particles showed protective e↵ects in
multivariable MR analyses, though the e↵ect sizes were smaller than those of the medium HDL traits. The mean
diameter of HDL particles (HDL-D) had almost no e↵ect on MI in the univariable MR analysis, but after adjusting
for the traditional lipid risk factors, it showed a harmful e↵ect.
Table 2 reports the estimated e↵ects of M-HDL-P, S-HDL-P, HDL-D, and traditional lipid traits (TG, LDL-C,












































































































































































































































































































































































































































Figure 1: Genetic correlation matrix of the 27 lipoprotein subfraction traits selected in phenotypic screening and 5
traditional lipid traits. White asterisk indicates the correlation is statistically significant after Bonferroni correction
for multiple comparisons at level 0.05.
particle sizes, we also included in the table the results of the multivariate MR analyses for the traditional lipid risk
factors only. Those baseline analyses suggested that HDL-C/ApoA1 had a weak, non-significant protective e↵ect
on CAD, which is consistent with prior studies [44, 49]. Adding S-HDL-P to the MR analysis did not substantially
alter the estimated e↵ects of the traditional lipid traits. However, when M-HDL-P or HDL-D was included in the
model, the estimated e↵ects of M-HDL-P and HDL-D changed substantially. In particular, when M-HDL-P was
included in the multivariable MR analyses, HDL-C/ApoA1 showed a harmful e↵ect on CAD. When HDL-D was
included, HDL-C/ApoA1 showed a protective e↵ect.
Genetic markers associated with HDL subfractions and CAD
We identified four genetic variants that are associated with S-HDL-P, M-HDL-P, or HDL-D, not associated with
LDL-C or ApoB, and associated with CAD: rs838880 (SCARB1 ), rs737337 (DOCK6 ), rs2943641 (IRS1 ), and
rs6065904 (PLTP) (Figure 3). These SNP-cis gene pairs are also supported by examining expression quantitative
trait loci (eQTL) in the tissue-specific GTEx data (Appendix 4). The first three variants were not associated with S-
HDL-P. However, they had uniformly positive associations with M-HDL-P, L-HDL-P, XL-HDL-P, HDL-D, ApoA1,
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Figure 2: Results of the Mendelian randomization analyses (false discover rate = 0.05): Estimated odds ratio [95%
confidence interval] per standard deviation increase of the selected lipoprotein measurements on MI or CAD.
HDL-P and M-HDL-P, negative associations with L-HDL-P, XL-HDL-P, HDL-D, negative but smaller associations
with ApoA1 and HDL-C, and a negative association with CAD.
Sensitivity and replicability analysis
We also investigated the e↵ects of lipoprotein subfractions and particle sizes on MI/CAD using multiple GWAS
datasets, MR designs and statistical methods. The results are provided in Appendix 3 and are generally in
agreement with the primary results reported above. The diagnostic plots for S-HDL-P and M-HDL-P did not
suggest evidence of violations of the instrument strength independent of direct e↵ect (InSIDE) assumption [50]
made by RAPS and GRAPPLE (Appendix 4).
4 Discussion
By using recent genetic data and Mendelian randomization, this study examines whether some lipoprotein subfrac-
tions and particle sizes, beyond the traditional lipid risk factors, may play a role in coronary artery disease. We
find that VLDL subfractions have extremely high genetic correlations with blood triglyceride level and thus o↵er
little extra value. We find some weak evidence that larger LDL particle size may have a small harmful e↵ect on
myocardial infarction and coronary artery disease.
Our main finding is that the size of HDL particles may play an important and previously undiscovered role.
Although the concentration and lipid content of small and medium HDL particles appear to be positively corre-
lated with HDL cholesterol and ApoA1, their genetic correlations are much smaller than 1, indicating possible
independent biological pathway(s). Moreover, the Mendelian randomization analyses suggested that the small and
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Table 2: Results of some multivariable Mendelian randomization analyses. Each row in the table corresponds to
a multivariable MR analysis with traditional lipid profile and the specified lipoprotein subfraction or particle size
trait. Reported numbers are the point estimates and 95% confidence intervals of the exposure e↵ect.
Trait E↵ect of TG E↵ect of LDL-C E↵ect of HDL-C E↵ect of Subfraction/Particle size
None 0.19 [0.09,0.29] 0.38 [0.33,0.44] -0.053 [-0.13,0.03]
M-HDL-P 0.37 [0.22,0.52] 0.39 [0.32,0.45] 0.30 [0.08,0.52] -0.69 [-1.09,-0.3]
S-HDL-P 0.23 [0.12,0.33] 0.45 [0.38,0.52] -0.11 [-0.2,-0.02] -0.33 [-0.52, -0.15]
HDL-D 0.11 [0.00,0.22] 0.42 [0.36,0.49] -0.44 [-0.69, -0.2] 0.33 [0.11,0.56]
E↵ect of TG E↵ect of ApoB E↵ect of ApoA1 E↵ect of Subfraction/Particle size
None 0.05 [-0.05,0.14] 0.49 [0.38,0.60] -0.095 [-0.21,0.02]
M-HDL-P -0.00 [-0.18,0.17] 0.50 [0.31,0.69] 0.13 [-0.06,0.32] -0.47 [-0.80, -0.15]
S-HDL-P 0.07 [-0.03,0.17] 0.53 [0.41,0.65] -0.13 [-0.25,-0.02] -0.24 [-0.40, -0.08]
HDL-D 0.06 [-0.04,0.15] 0.61 [0.47,0.76] -0.46 [-0.73,-0.19] 0.30 [0.08,0.52]
medium HDL particles may have protective e↵ects on CAD. We also find that larger HDL mean particle diameter
may have a harmful e↵ect on CAD. Finally, we identified four potential genetic markers for HDL particle size that
are independent of LDL cholesterol and ApoB.
There has been a heated debate on the role of HDL particles in CAD in recent years following the failure of
several trials for CETP inhibitors [51–53] and recombinant ApoA1 [54] targeting HDL cholesterol. Observational
epidemiology studies have long demonstrated strong inverse association between HDL cholesterol and the risk of
CAD or MI [55–57], but conflicting evidence has been found in MR studies. In an influential study, Voight and
collaborators found that the genetic variants associated with HDL cholesterol had varied associations with CAD and
that almost all variants suggesting a protective e↵ect of HDL cholesterol were also associated with LDL cholesterol
or triglycerides [58]. Other MR studies also found that the e↵ect of HDL cholesterol on CAD is heterogeneous [38]
or attenuated after adjusting for LDL cholesterol and triglycerides [59, 60].
Notice that the harmful e↵ect of larger HDL particle diameter found in this study relies on including HDL-C or
ApoA1 in the multivariable MR analysis. Thus, the role of HDL particles in preventing CAD may be more compli-
cated than, for example, that of LDL cholesterol or ApoB. It is possible that HDL cholesterol, HDL subfractions,
and HDL particle size are all phenotypic markers for some underlying causal mechanism. A related theory is the
HDL function hypothesis [61]. Cholesterol e✏ux capacity, a measure of HDL function, has been documented as
superior to HDL-C in predicting CVD risk [62, 63]. Recent epidemiologic studies found that HDL particle size is
positively associated with cholesterol e✏ux capacity in post-menopausal women [64] and in an asymptomatic older
cohort [65]. However, mechanistic e✏ux studies showed that small HDL particles actually mediate more cholesterol
e✏ux [66, 67]. A likely explanation of this seeming contradiction is that a high concentration of small HDL particles
in the serum may mark a block in maturation of small HDL particles [65]. This can also partly explain our finding
that small HDL traits have a smaller e↵ect than medium HDL traits, as increased medium HDL might indicate
successful maturation of small HDL particles.
Among the reported genetic markers, SCARB1 and PLTP have established relations to HDL metabolism and
CAD. SCARB1 encodes a plasma membrane receptor for HDL and is involved in hepatic uptake of cholesterol
from peripheral tissues. Recently, a rare mutation (P376L) of SCARB1 was reported to raise HDL-C level and
increase CAD risk [68, 69]. This is opposite direction to the conventional belief that HDL-C is protective and could
be explained by HDL dysfunction. PLTP encodes the phospholipid transfer protein and mediates the transfer of
phospholipid and cholesterol from LDL and VLDL to HDL. As a result, PLTP plays a complex but pivotal role
in HDL particle size and composition. Several studies have suggested that high PLTP activity is a risk factor for
CAD [70–72].
Our study should be viewed in the context of its limitations, in particular, the inherent limitations of the
summary-data Mendelian randomization design. Any causal inference from non-experimental data makes un-
verifiable assumptions, so does our study. Conventional MR studies assume that the genetic variants are valid
instrumental variables. The statistical methods used by us make less stringent assumptions about the instrumental
variables, but those assumptions could still be violated even though our model diagnosis does not suggest evidence
against the InSIDE assumption. Our study did not adjust for other risk factors for CAD such as body mass index,
blood pressure, and smoking. All the GWAS datasets used in this study are from the European population, so the
same conclusions might not generalize to other populations. Furthermore, our study used GWAS datasets from
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Figure 3: Genetic markers for HDL size (with risk alleles) and their associations with various lipid traits.
heterogeneous subpopulations, which may also introduce bias [73]. We also did not use more than one subfraction
traits as exposures in multivariable MR because of their high genetic correlations. Alternative statistical methods
could be used to select the best causal risk factor from high-throughput experiments [74]. Finally, as pointed out by
revieweres, triglycerides has a greater intra-individual biological variability than HDL particle size. It is likely that
triglycerides and HDL size represent a gene/environment interaction with a very large environmental component.
Further investigations are needed to fully understand this mechanism.
Recently, a NMR spectroscopy method has been developed to estimate HDL cholesterol e✏ux capacity from
serum [75]. That method can form the basis of a genetic analysis of HDL cholesterol e✏ux capacity and may
complement the results here. We believe more laboratorial and epidemiological research is needed to clarify the
roles of HDL subfractions and particle size in cardiovascular diseases.
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Appendix 1 Lipid and lipoprotein traits
Two published GWAS of the human lipidome [31, 32] measured lipoprotein subfractions and particle sizes using
NMR spectroscopy. We investigated the 82 lipid and lipoprotein traits measured in these studies that are related
to very-low-density lipoprotein (VLDL), LDL, and HDL subfractions and particle sizes. All the subfraction traits
are named using three components separated by hyphen: the first indicates the size (XS, S, M, L, XL, XXL); the
second indicates the category according to the lipoprotein density (VLDL, LDL, IDL, HDL); the third indicates
the measurement (C for total cholesterol, CE for cholesterol esters, FC for free cholesterol, L for total lipids, P for
particle concentration, PL for phospholipids, TG for triglycerides). A full list of lipid and lipoprotein traits used
in our study can be found in Appendix 1-Table 1 below.
Appendix 1-Table 1: All 82 traits included in this study and whether they are measured in the Kettunen and Davis
GWAS (NA means not available).
Trait Description Kettunen Davis
VLDL traits and total triglycerides
TG Total triglycerides
VLDL-D VLDL diameter
XS-VLDL-L Total lipids in very small VLDL NA
XS-VLDL-P Concentration of very small VLDL particles
XS-VLDL-PL Phospholipids in very small VLDL
XS-VLDL-TG Triglycerides in very small VLDL
S-VLDL-C Total cholesterol in small VLDL
S-VLDL-FC Free cholesterol in small VLDL
S-VLDL-L Total lipids in small VLDL NA
S-VLDL-P Concentration of small VLDL particles
S-VLDL-PL Phospholipids in small VLDL
S-VLDL-TG Triglycerides in small VLDL
M-VLDL-C Total cholesterol in medium VLDL
M-VLDL-CE Cholesterol esters in medium VLDL
M-VLDL-FC Free cholesterol in medium VLDL
M-VLDL-L Total lipids in medium VLDL NA
M-VLDL-P Concentration of medium VLDL particles
M-VLDL-PL Phospholipids in medium VLDL
M-VLDL-TG Triglycerides in medium VLDL
L-VLDL-C Total cholesterol in large VLDL
L-VLDL-CE Cholesterol esters in large VLDL
L-VLDL-FC Free cholesterol in large VLDL
L-VLDL-L Total lipids in large VLDL NA
L-VLDL-P Concentration of large VLDL particles
L-VLDL-PL Phospholipids in large VLDL
L-VLDL-TG Triglycerides in large VLDL
XL-VLDL-L Total lipids in very large VLDL NA
XL-VLDL-P Concentration of very large VLDL particles
XL-VLDL-PL Phospholipids in very large VLDL
XL-VLDL-TG Triglycerides in very large VLDL
XXL-VLDL-L Total lipids in chylomicrons and extremely very large VLDL NA
XXL-VLDL-P Concentration of chylomicrons and extremely very large VLDL particles
XXL-VLDL-PL Phospholipids in chylomicrons and extremely very large
XXL-VLDL-TG Triglycerides in chylomicrons and extremely very large
LDL and IDL traits
LDL-C Total cholesterol in LDL
ApoB Apolipoprotein B
LDL-D LDL diameter
S-LDL-C Total cholesterol in small LDL
S-LDL-L Total lipids in small LDL NA
1
S-LDL-P Phospholipids in small LDL
M-LDL-C Total cholesterol in medium LDL
M-LDL-CE Cholesterol esters in medium LDL
M-LDL-L Total lipids in medium LDL NA
M-LDL-P Concentration of medium LDL particles
M-LDL-PL Phospholipids in medium LDL
L-LDL-C Total cholesterol in large LDL
L-LDL-CE Cholesterol esters in large LDL
L-LDL-FC Free cholesterol in large LDL
L-LDL-L Total lipids in large LDL NA
L-LDL-P Concentration of large LDL particles
L-LDL-PL Phospholipids in large LDL
IDL-C Total cholesterol in IDL
IDL-FC Free cholesterol in IDL
IDL-L Total lipids in IDL NA
IDL-P Concentration of IDL particles
IDL-PL Phospholipids in IDL
IDL-TG Triglycerides in IDL
HDL traits
HDL-C Total cholesterol in HDL
ApoA1 Apolipoprotein A1
HDL-D HDL diameter
S-HDL-L Total lipids in small HDL NA
S-HDL-P Concentration of small HDL particles
S-HDL-TG Triglycerides in small HDL
M-HDL-C Total cholesterol in medium HDL
M-HDL-CE Cholesterol esters in medium HDL
M-HDL-FC Free cholesterol in medium HDL
M-HDL-L Total lipids in medium HDL NA
M-HDL-P Concentration of medium HDL particles
M-HDL-PL Phospholipids in medium HDL
L-HDL-C Total cholesterol in large HDL
L-HDL-CE Cholesterol esters in large HDL
L-HDL-FC Free cholesterol in large HDL
L-HDL-L Total lipids in large HDL NA
L-HDL-P Concentration of large HDL particles
L-HDL-PL Phospholipids in large HDL
XL-HDL-C Total cholesterol in very large HDL
XL-HDL-CE Cholesterol esters in very large HDL
XL-HDL-FC Free cholesterol in very large HDL
XL-HDL-L Total lipids in very large HDL NA
XL-HDL-P Concentration of very large HDL particles
XL-HDL-PL Phospholipids in very large HDL
XL-HDL-TG Triglycerides in very large HDL
2
Appendix 2 Genetic Correlations
We estimated the genetic correlation between lipoprotein subfractions, particle sizes, and traditional lipid risk
factors using the LD score regression [37]. Appendix 2-Figure 1 to 3 show the estimated genetic correlation matrix
between selected traits using di↵erent datasets. Below the figures, Appendix 2-Table 1 shows the estimated genetic
correlations of the lipoprotein subbfractions with the traditional lipid risk factors using the Davis GWAS. The





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 2-Figure 3: Genetic correlations computed by meta-analyzing the results in Appendix 2-Figure 1 and 2.
5
Appendix 2-Table 1: Estimated genetic correlation (standard error) of the lipoprotein subfractions with the tradi-
tional lipid risk factors using the Davis GWAS. Bolded estimates are above 0.8 and the corresponding traits were
removed in phenotypic screening.
Trait ApoA1 ApoB HDL-C LDL-C TG
S-HDL-L 0.31 (0.28) 0.34 (0.25) 0.13 (0.26) 0.27 (0.3) 0.2 (0.22)
S-HDL-P 0.36 (0.24) 0.27 (0.22) -0.01 (0.22) 0.1 (0.31) 0.48 (0.17)
S-HDL-TG -0.13 (0.25) 0.77 (0.13) -0.66 (0.15) 0.13 (0.28) 1.03 (0.07)
M-HDL-C 0.65 (0.14) -0.18 (0.2) 0.81 (0.09) -0.09 (0.25) -0.34 (0.17)
M-HDL-CE 0.68 (0.14) -0.23 (0.21) 0.57 (0.12) -0.24 (0.24) -0.32 (0.18)
M-HDL-FC 0.67 (0.12) -0.08 (0.21) 0.83 (0.08) 0.04 (0.24) -0.28 (0.18)
M-HDL-L 0.71 (0.15) 0.02 (0.27) 0.52 (0.17) -0.03 (0.29) -0.19 (0.25)
M-HDL-P 0.75 (0.12) 0.15 (0.23) 0.46 (0.14) 0.08 (0.26) 0 (0.19)
M-HDL-PL 0.69 (0.13) 0.04 (0.22) 0.65 (0.11) 0.02 (0.25) -0.04 (0.19)
L-HDL-C 0.76 (0.11) -0.42 (0.13) 0.95 (0.02) -0.1 (0.18) -0.62 (0.09)
L-HDL-CE 0.82 (0.1) -0.4 (0.12) 0.93 (0.04) -0.16 (0.17) -0.62 (0.09)
L-HDL-FC 0.66 (0.12) -0.46 (0.13) 0.92 (0.03) -0.13 (0.18) -0.7 (0.08)
L-HDL-L 0.81 (0.11) -0.29 (0.15) 0.74 (0.07) -0.15 (0.18) -0.56 (0.12)
L-HDL-P 0.79 (0.09) -0.35 (0.13) 0.82 (0.05) -0.12 (0.16) -0.61 (0.09)
L-HDL-PL 0.77 (0.09) -0.34 (0.13) 0.79 (0.05) -0.12 (0.17) -0.61 (0.09)
XL-HDL-C 0.75 (0.16) -0.25 (0.19) 0.9 (0.1) 0.4 (0.27) -0.63 (0.13)
XL-HDL-CE 0.82 (0.16) -0.17 (0.19) 0.82 (0.09) 0.41 (0.27) -0.54 (0.12)
XL-HDL-FC 0.72 (0.14) -0.37 (0.18) 0.94 (0.08) 0.17 (0.23) -0.71 (0.11)
XL-HDL-L 0.93 (0.16) -0.08 (0.25) 0.68 (0.14) 0.1 (0.27) -0.35 (0.2)
XL-HDL-P 0.81 (0.13) -0.32 (0.16) 0.86 (0.08) 0.17 (0.21) -0.69 (0.11)
XL-HDL-PL 0.76 (0.12) -0.41 (0.15) 0.83 (0.07) -0.09 (0.18) -0.7 (0.09)
XL-HDL-TG 0.72 (0.13) 0.49 (0.17) 0.33 (0.13) 0.13 (0.26) 0.3 (0.15)
HDL-D 0.7 (0.11) -0.36 (0.13) 0.8 (0.06) -0.08 (0.17) -0.64 (0.09)
IDL-C 0.38 (0.21) 0.58 (0.19) 0.07 (0.19) 0.8 (0.14) 0.39 (0.17)
IDL-FC 0.23 (0.2) 0.78 (0.12) -0.05 (0.17) 0.61 (0.19) 0.44 (0.15)
IDL-L 0.38 (0.23) 0.65 (0.18) 0.05 (0.2) 0.64 (0.2) 0.47 (0.17)
IDL-P 0.31 (0.2) 0.66 (0.14) -0.04 (0.17) 0.82 (0.13) 0.49 (0.14)
IDL-PL 0.25 (0.23) 0.83 (0.1) -0.12 (0.19) 0.7 (0.19) 0.64 (0.15)
IDL-TG 0.22 (0.18) 0.82 (0.08) -0.2 (0.13) 0.56 (0.15) 0.67 (0.08)
S-LDL-C 0.11 (0.28) 0.66 (0.18) -0.16 (0.22) 0.44 (0.34) 0.58 (0.14)
S-LDL-L 0.26 (0.23) 0.66 (0.17) -0.06 (0.21) 0.62 (0.21) 0.58 (0.13)
S-LDL-P 0.34 (0.2) 0.68 (0.15) -0.02 (0.19) 0.63 (0.18) 0.58 (0.13)
M-LDL-C 0.15 (0.26) 0.63 (0.18) 0.22 (0.22) 0.87 (0.08) 0.13 (0.23)
M-LDL-CE 0.3 (0.23) 0.61 (0.2) 0.05 (0.21) 0.65 (0.2) 0.45 (0.16)
M-LDL-L 0.29 (0.22) 0.63 (0.18) 0.01 (0.21) 0.66 (0.19) 0.5 (0.15)
M-LDL-P 0.29 (0.23) 0.63 (0.18) -0.01 (0.21) 0.65 (0.21) 0.51 (0.15)
M-LDL-PL 0.2 (0.24) 0.69 (0.16) 0.11 (0.2) 0.89 (0.06) 0.18 (0.22)
L-LDL-C 0.25 (0.24) 0.58 (0.21) 0.25 (0.22) 0.68 (0.19) 0.23 (0.21)
L-LDL-CE 0.3 (0.23) 0.58 (0.22) 0.05 (0.21) 0.65 (0.21) 0.41 (0.17)
L-LDL-FC 0.31 (0.24) 0.57 (0.22) 0.33 (0.23) 0.7 (0.18) 0.13 (0.23)
L-LDL-L 0.31 (0.23) 0.61 (0.2) 0.04 (0.21) 0.65 (0.21) 0.44 (0.17)
L-LDL-P 0.31 (0.23) 0.63 (0.19) 0.02 (0.21) 0.65 (0.21) 0.47 (0.16)
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L-LDL-PL 0.27 (0.25) 0.61 (0.2) 0.24 (0.22) 0.67 (0.2) 0.27 (0.2)
LDL-D -0.33 (0.25) -0.22 (0.23) -0.15 (0.21) -0.15 (0.29) -0.37 (0.16)
XS-VLDL-L 0.25 (0.23) 0.8 (0.08) -0.2 (0.17) 0.61 (0.14) 0.73 (0.09)
XS-VLDL-P 0.17 (0.18) 0.83 (0.07) -0.26 (0.13) 0.57 (0.13) 0.71 (0.07)
XS-VLDL-PL 0.21 (0.19) 0.78 (0.09) -0.15 (0.15) 0.74 (0.14) 0.57 (0.11)
XS-VLDL-TG 0.06 (0.18) 0.83 (0.08) -0.37 (0.11) 0.56 (0.13) 0.85 (0.04)
S-VLDL-FC -0.08 (0.2) 0.94 (0.05) -0.49 (0.12) 0.59 (0.12) 0.92 (0.03)
S-VLDL-L -0.12 (0.24) 0.7 (0.08) -0.46 (0.15) 0.5 (0.14) 0.8 (0.05)
S-VLDL-P -0.09 (0.19) 0.78 (0.07) -0.48 (0.11) 0.5 (0.14) 0.95 (0.02)
S-VLDL-PL -0.03 (0.2) 0.82 (0.08) -0.43 (0.12) 0.44 (0.17) 0.92 (0.03)
S-VLDL-TG -0.1 (0.2) 0.9 (0.08) -0.49 (0.11) 0.49 (0.15) 0.98 (0.01)
S-VLDL-C 0.01 (0.2) 0.9 (0.06) -0.39 (0.13) 0.61 (0.15) 0.89 (0.05)
M-VLDL-C -0.01 (0.2) 0.8 (0.09) -0.47 (0.12) 0.41 (0.18) 0.95 (0.02)
M-VLDL-CE 0.01 (0.19) 0.78 (0.08) -0.43 (0.12) 0.5 (0.15) 0.9 (0.03)
M-VLDL-FC 0 (0.21) 0.83 (0.09) -0.48 (0.12) 0.4 (0.18) 0.97 (0.01)
M-VLDL-L -0.1 (0.24) 0.66 (0.11) -0.48 (0.15) 0.4 (0.18) 0.8 (0.05)
M-VLDL-P -0.06 (0.19) 0.78 (0.1) -0.46 (0.12) 0.43 (0.16) 0.98 (0.02)
M-VLDL-PL 0.03 (0.21) 0.85 (0.09) -0.48 (0.12) 0.4 (0.18) 0.98 (0.01)
M-VLDL-TG -0.02 (0.21) 0.82 (0.11) -0.5 (0.13) 0.33 (0.19) 0.98 (0.02)
L-VLDL-C -0.05 (0.2) 0.83 (0.12) -0.55 (0.12) 0.36 (0.19) 1 (0.02)
L-VLDL-CE 0 (0.19) 0.78 (0.12) -0.44 (0.12) 0.43 (0.19) 0.93 (0.03)
L-VLDL-FC -0.03 (0.2) 0.84 (0.12) -0.53 (0.13) 0.36 (0.19) 1 (0.02)
L-VLDL-L -0.06 (0.24) 0.66 (0.14) -0.47 (0.16) 0.36 (0.2) 0.86 (0.05)
L-VLDL-P -0.02 (0.21) 0.72 (0.12) -0.44 (0.13) 0.33 (0.18) 0.98 (0.02)
L-VLDL-PL 0.01 (0.21) 0.86 (0.12) -0.53 (0.13) 0.3 (0.2) 1.04 (0.03)
L-VLDL-TG -0.06 (0.21) 0.78 (0.12) -0.54 (0.13) 0.26 (0.19) 1 (0.02)
XL-VLDL-L -0.08 (0.24) 0.7 (0.15) -0.52 (0.16) 0.43 (0.2) 0.85 (0.05)
XL-VLDL-P -0.06 (0.2) 0.76 (0.12) -0.48 (0.13) 0.44 (0.18) 0.95 (0.03)
XL-VLDL-PL -0.09 (0.23) 0.82 (0.13) -0.62 (0.15) 0.32 (0.21) 1.06 (0.04)
XL-VLDL-TG -0.14 (0.21) 0.86 (0.13) -0.65 (0.13) 0.34 (0.19) 1.03 (0.04)
XXL-VLDL-L -0.07 (0.25) 0.65 (0.16) -0.5 (0.17) 0.38 (0.22) 0.83 (0.06)
XXL-VLDL-P 0.17 (0.2) 0.72 (0.15) -0.3 (0.15) 0.39 (0.21) 0.86 (0.07)
XXL-VLDL-PL -0.3 (0.24) 0.66 (0.17) -0.8 (0.16) 0.22 (0.21) 1.06 (0.06)
XXL-VLDL-TG -0.21 (0.25) 0.64 (0.16) -0.7 (0.15) 0.22 (0.22) 1.08 (0.05)
VLDL-D -0.22 (0.2) 0.55 (0.14) -0.53 (0.12) 0.12 (0.19) 0.86 (0.04)
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Appendix 3 Mendelian randomization
We implemented several Mendelian randomization (MR) designs and statistical methods to estimate the causal
e↵ect of lipoprotein subfractions and particles sizes on coronary artery disease. In general, we adopted the three-
sample summary data MR design described in Zhao et al. [38], Wang et al. [44] and we swapped the roles of the
GWAS datasets whenever permitted by the statistical methods. More specifically, the statistical methods we used
for univariable MR (RAPS, IVW, weighted median) require that the GWAS datasets for obtaining instruments,
SNP e↵ects on the exposure, and SNP e↵ects on the outcome must have no overlapping sample. The multivariable
MR method we used (GRAPPLE) allows the exposure and outcome GWAS to be dependent and estimates the
proportion of overlapping sample. However, GRAPPLE still requires that the selection GWAS uses an non-
overlapping sample.
The MR designs we implemented in this study are summarized in Appendix 3-Table 1. We considered two
ways of instrument selection for univariable MR. In “traditional selection”, the traditional lipid traits were used
to select the instruments for the corresponding subfraction traits. That is, HDL-C was used to select SNPs for
HDL subfractions and particle size, LDL-C for IDL and LDL subfractions and particle size, and TG for VLDL
subfractions and particle size. This tends to select more instruments because the GWAS for traditional lipid traits
had a larger sample size. In “subfraction selection”, the instrumental SNPs were selected for each lipoprotein
subfraction and particle size using the same or closest trait in the selection GWAS. For example, if the exposure
under investigation is S-HDL-L but it is not measured in the Davis GWAS (if it is used for selection), S-HDL-P is
used instead for instrument selection.
For multivariable MR, we considered two models with di↵erent sets of exposures: TG, LDL-C, HDL-C, and the
subfraction/particle size under investigation; TG, ApoB, ApoA1, and the subfraction/particle size under investi-
gation. SNPs were selected as potential instruments if they were associated (p-value  10 4) with at least one of
the four exposures. LD clumping was then used to obtain independent instruments, as described in Materials and
Methods.
We briefly comment on the statistical methods used in univariable MR. All the three methods we used—RAPS,
IVW, weighted median—require that the exposure GWAS and outcome GWAS have non-overlapping samples.
RAPS and weighted median can provide consistent estimate of the causal e↵ect even when some of the genetic
variants are not valid instruments, provided that the direct e↵ects of the genetic variants are independent of the
strength of their associations with the exposure. The last condition is called the Instrument Strength Independent
of Direct E↵ect (InSIDE) assumption in the MR literature [50]. RAPS is also robust to idiosyncratically large direct
e↵ect [43]. Because IVW and weighted median can be severely biased by weak instruments [43], we only used them
with the set of SNPs that have genome-wide significant association (p-value  5 ⇥ 10 8) with the exposure. In
comparison, RAPS does not su↵er from weak instrument bias and we used it with all the SNPs obtained by LD
clumping without any p-value threshold.
Below, Appendix 3-Figure 1 shows the MR results for the 27 lipoprotein measurements selected in phenotypic
screening. Estimates that are statistically significant at a false discovery rate of 0.05 are shown in Figure 2 of the
main paper. Appendix 3-Table 2 shows the estimated e↵ect of all the lipoprotein subfractions and particle sizes
on myocardial infarction or coronary artery disease in various MR designs. Full results of the multivariable MR
analyses, including the estimated e↵ects of the traditional lipid risk factors, can be found in Appendix 3-Table 5
and 6. The results of the univariable MR analyses using IVW and weighted median estimators can be found in
Appendix 3-Table 3 and 4.
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MR Design Selection Exposure Outcome Reported in
Univariable
(traditional selection)
GERA Davis CARDIoGRAMplusC4D Appendix 3-Table 2 to 4
GERA Davis UK Biobank Appendix 3-Table 2 to 4
GERA Kettunen UK Biobank Appendix 3-Table 2 to 4
GLGC Davis UK Biobank Appendix 3-Table 2 to 4
Univariable
(subfraction selection)
Davis Kettunen UK Biobank
Figure 2;
Appendix 3-Figure 1 and appendix 3-table 2 to 4
Kettunen Davis UK Biobank Appendix 3-Figure 1 and appendix 3-table 2 to 4
Multivariable Davis, GERA Kettunen, GLGC
CARDIoGRAMplusC4D
+ UK Biobank
Figure 2, Table 2;
Appendix 3-Figure 1 and appendix 3-table 2 to 4
Appendix 3-Table 1: Three-sample Mendelian randomization designs.
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 HDL−C, LDL−C, TG
Appendix 3-Figure 1: Mendelian randomization results for the 27 lipoprotein measurements selected in phenotypic screening.
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In the tables below, Red indicates p-value is significant (at level 0.05) after Bonferroni correction for all the results in the corresponding table and blue
indicates p-value  0.05
Appendix 3-Table 2: Mendelian randomization results using all selected SNPs (univariable MR using RAPS and multivariable MR using GRAPPLE).
Method: RAPS/GRAPPLE + All SNPs
Screening GERA GERA GERA GLGC Davis Kettunen GERA + Davis GERA + Davis
Exposure Davis Davis Kettunen Davis Kettunen Davis GLGC + Kettunen GLGC + Kettunen
Outcome CAD UKB UKB UKB UKB UKB CAD + UKB CAD + UKB
Adjusted HDL-C + LDL-C + TG ApoA1 + ApoB + TG
VLDL traits
TG .258 (.053) .296 (.075) NA .262 (.06) NA .289 (.068) NA NA
VLDL-D -.099 (.049) .028 (.074) .072 (.073) .116 (.065) -.163 (.067) -.204 (.071) -.588 (.094) -.32 (.112)
XS-VLDL-L NA NA .368 (.064) NA .429 (.059) NA .132 (.119) .084 (.141)
XS-VLDL-P .17 (.031) .26 (.048) .367 (.065) .248 (.047) .429 (.06) .338 (.056) .118 (.125) .061 (.158)
XS-VLDL-PL .191 (.034) .284 (.055) .386 (.069) .278 (.052) .449 (.049) .435 (.049) .159 (.12) .253 (.135)
XS-VLDL-TG .201 (.034) .3 (.053) .388 (.068) .283 (.046) .372 (.063) .326 (.055) -.157 (.187) -.248 (.15)
S-VLDL-C .294 (.06) .343 (.076) NA .322 (.063) NA .424 (.094) -1.035 (.323) -1.265 (.568)
S-VLDL-FC .243 (.051) .303 (.068) .389 (.079) .286 (.056) .489 (.071) .416 (.074) -1.027 (.337) -.489 (.213)
S-VLDL-L NA NA .356 (.075) NA .376 (.072) NA -.898 (.28) -1.629 (.586)
S-VLDL-P .226 (.047) .288 (.068) .343 (.074) .261 (.054) .359 (.069) .271 (.094) -1.245 (.463) -1.644 (.606)
S-VLDL-PL .228 (.047) .294 (.067) .372 (.074) .273 (.054) .365 (.066) .336 (.063) -.613 (.182) -1.213 (.478)
S-VLDL-TG .223 (.049) .283 (.071) .323 (.073) .25 (.055) .327 (.071) .275 (.067) NaN -.301 (.108)
M-VLDL-C .253 (.053) .304 (.078) .327 (.074) .276 (.06) .368 (.07) .312 (.079) -1.433 (.451) -.373 (.118)
M-VLDL-CE .248 (.051) .309 (.074) .344 (.077) .285 (.058) .369 (.073) .295 (.069) -1.035 (.293) -.995 (.338)
M-VLDL-FC .245 (.058) .283 (.082) .31 (.076) .259 (.063) .341 (.069) .341 (.068) -1.412 (.444) -.799 (.311)
M-VLDL-L NA NA .311 (.079) NA .358 (.078) NA -1.878 (.75) -.298 (.098)
M-VLDL-P .25 (.062) .282 (.083) .305 (.081) .247 (.065) .293 (.089) .269 (.065) -1.974 (.745) -.312 (.096)
M-VLDL-PL .248 (.056) .295 (.077) .318 (.075) .259 (.06) .351 (.071) .31 (.063) -2.012 (.943) -.297 (.106)
M-VLDL-TG .205 (.064) .248 (.087) .3 (.082) .224 (.067) .275 (.092) .246 (.074) -2.133 (.879) -.806 (.455)
L-VLDL-C .299 (.067) .304 (.1) .297 (.081) .291 (.077) .289 (.085) .317 (.077) -1.254 (.297) -.609 (.337)
L-VLDL-CE .247 (.061) .282 (.088) .282 (.082) .282 (.072) .285 (.082) .3 (.112) -1.081 (.282) -.673 (.217)
L-VLDL-FC .316 (.076) .294 (.108) .311 (.083) .287 (.081) .351 (.087) .298 (.078) -1.274 (.308) -.619 (.291)
L-VLDL-L NA NA .36 (.096) NA .32 (.102) NA -1.277 (.313) -.532 (.278)
L-VLDL-P .268 (.073) .287 (.103) .281 (.085) .262 (.075) .219 (.086) .255 (.082) -1.357 (.344) -.617 (.229)
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Method: RAPS/GRAPPLE + All SNPs
Screening GERA GERA GERA GLGC Davis Kettunen GERA + Davis GERA + Davis
Exposure Davis Davis Kettunen Davis Kettunen Davis GLGC + Kettunen GLGC + Kettunen
Outcome CAD UKB UKB UKB UKB UKB CAD + UKB CAD + UKB
Adjusted HDL-C + LDL-C + TG ApoA1 + ApoB + TG
L-VLDL-PL .322 (.071) .318 (.102) .346 (.089) .283 (.077) .397 (.101) .351 (.076) NaN -.287 (.104)
L-VLDL-TG .243 (.077) .238 (.104) .332 (.094) .246 (.08) .26 (.103) .324 (.082) -1.428 (.372) -.252 (.091)
XL-VLDL-L NA NA .289 (.098) NA .435 (.14) NA -1.069 (.203) -.577 (.249)
XL-VLDL-P .27 (.074) .262 (.099) .281 (.093) .279 (.084) .404 (.122) .251 (.084) -1.209 (.238) -.373 (.109)
XL-VLDL-PL .446 (.09) .344 (.13) .31 (.093) .361 (.118) .375 (.12) .408 (.102) -1.214 (.257) -.583 (.268)
XL-VLDL-TG .294 (.092) .229 (.109) .261 (.094) .284 (.095) .365 (.111) .319 (.093) -1.071 (.205) -.603 (.248)
XXL-VLDL-L NA NA .397 (.108) NA .312 (.108) NA -1.355 (.318) -.402 (.144)
XXL-VLDL-P .308 (.08) .327 (.096) .378 (.097) .297 (.088) .32 (.101) .227 (.073) -1.639 (.502) -1.089 (.449)
XXL-VLDL-PL .338 (.091) .346 (.103) .342 (.103) .351 (.103) .282 (.114) .317 (.086) -1.259 (.262) -.814 (.344)
XXL-VLDL-TG .384 (.108) .374 (.124) .348 (.1) .433 (.121) .304 (.138) .359 (.18) -1.202 (.262) -1.075 (.402)
IDL/LDL traits
LDL-C .523 (.043) .512 (.053) .514 (.042) .473 (.055) .435 (.048) .464 (.048) NA .319 (.182)
ApoB .605 (.056) .55 (.062) .551 (.052) .543 (.069) .61 (.066) .613 (.06) -.532 (.191) NA
LDL-D .271 (.215) .452 (.299) 2.064 (.233) .831 (.684) .328 (.073) .201 (.055) .145 (.061) .119 (.071)
S-LDL-C .624 (.053) .589 (.061) .539 (.048) .537 (.067) .474 (.056) .48 (.05) -.282 (.152) .08 (.238)
S-LDL-L NA NA .561 (.047) NA .473 (.057) NA -.251 (.145) -.005 (.29)
S-LDL-P .621 (.057) .581 (.065) .56 (.049) .558 (.073) .459 (.061) .546 (.063) -.266 (.151) -.362 (.596)
M-LDL-C .648 (.055) .607 (.062) .545 (.044) .545 (.068) .455 (.049) .557 (.054) -.271 (.162) -.169 (.909)
M-LDL-CE .643 (.056) .601 (.062) .564 (.042) .545 (.069) .467 (.05) .55 (.055) -.088 (.188) NaN
M-LDL-L NA NA .559 (.042) NA .461 (.049) NA -.069 (.191) NaN
M-LDL-P .638 (.056) .597 (.062) .557 (.043) .54 (.069) .472 (.051) .46 (.05) -.179 (.174) .432 (.31)
M-LDL-PL .658 (.063) .605 (.067) .556 (.047) .571 (.077) .506 (.053) .559 (.057) -.407 (.162) -.566 (.839)
L-LDL-C .627 (.053) .577 (.059) .515 (.042) .504 (.063) .465 (.048) .488 (.052) -.059 (.261) NaN
L-LDL-CE .638 (.055) .589 (.06) .555 (.041) .514 (.065) .463 (.049) .493 (.054) .116 (.321) .461 (.213)
L-LDL-FC .609 (.051) .557 (.057) .503 (.041) .491 (.06) .468 (.047) .457 (.052) .223 (.315) NaN
L-LDL-L NA NA .543 (.04) NA .468 (.047) NA .167 (.273) NaN
L-LDL-P .606 (.052) .559 (.058) .545 (.041) .49 (.062) .484 (.046) .494 (.048) .084 (.213) NaN
L-LDL-PL .61 (.053) .558 (.058) .515 (.043) .492 (.063) .528 (.048) .502 (.052) -.036 (.195) NaN
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Method: RAPS/GRAPPLE + All SNPs
Screening GERA GERA GERA GLGC Davis Kettunen GERA + Davis GERA + Davis
Exposure Davis Davis Kettunen Davis Kettunen Davis GLGC + Kettunen GLGC + Kettunen
Outcome CAD UKB UKB UKB UKB UKB CAD + UKB CAD + UKB
Adjusted HDL-C + LDL-C + TG ApoA1 + ApoB + TG
IDL-C .596 (.054) .55 (.059) .562 (.042) .481 (.064) .511 (.047) .423 (.051) .192 (.229) .769 (.501)
IDL-FC .586 (.054) .539 (.059) .525 (.044) .494 (.063) .44 (.044) .402 (.05) .19 (.156) .33 (.127)
IDL-L NA NA .57 (.043) NA .494 (.048) NA .148 (.175) .444 (.328)
IDL-P .566 (.052) .536 (.059) .575 (.044) .488 (.065) .434 (.049) .412 (.051) .153 (.148) .292 (.173)
IDL-PL .583 (.052) .533 (.058) .532 (.045) .489 (.064) .471 (.047) .396 (.05) .153 (.18) .406 (.184)
IDL-TG .603 (.066) .595 (.075) .658 (.063) .567 (.085) .432 (.056) .315 (.053) .11 (.103) .047 (.135)
HDL traits
HDL-C -.117 (.031) -.199 (.045) -.136 (.055) -.317 (.052) -.045 (.059) -.108 (.05) NA NaN
ApoA1 -.119 (.042) -.193 (.06) .023 (.058) -.264 (.071) .075 (.064) -.13 (.068) -.481 (.271) NA
HDL-D -.008 (.027) -.124 (.041) .004 (.046) -.092 (.048) .067 (.045) .007 (.041) .333 (.114) .296 (.1)
S-HDL-L NA NA -.098 (.095) NA -.037 (.085) NA -.312 (.106) -.224 (.087)
S-HDL-P -.265 (.084) -.362 (.113) -.13 (.092) -.317 (.119) -.053 (.081) -.08 (.094) -.331 (.095) -.24 (.083)
S-HDL-TG .354 (.072) .386 (.088) .65 (.089) .475 (.097) .351 (.087) .283 (.073) .253 (.637) -.044 (.466)
M-HDL-C -.323 (.058) -.43 (.079) -.364 (.085) -.376 (.091) -.46 (.104) -.434 (.075) -.508 (.165) -.442 (.143)
M-HDL-CE -.333 (.058) -.458 (.078) -.372 (.09) -.385 (.087) -.542 (.105) -.443 (.071) -.487 (.157) -.413 (.137)
M-HDL-FC -.275 (.065) -.319 (.08) -.262 (.083) -.313 (.092) -.313 (.094) -.409 (.082) -.649 (.225) -.408 (.166)
M-HDL-L NA NA -.311 (.095) NA -.474 (.123) NA -.606 (.188) -.485 (.155)
M-HDL-P -.298 (.06) -.394 (.086) -.273 (.101) -.373 (.1) -.565 (.131) -.307 (.079) -.694 (.204) -.472 (.166)
M-HDL-PL -.265 (.058) -.346 (.083) -.25 (.09) -.335 (.096) -.358 (.104) -.3 (.072) -.632 (.191) -.486 (.171)
L-HDL-C -.067 (.03) -.144 (.044) -.139 (.051) -.144 (.05) -.147 (.052) -.049 (.045) .516 (.213) .575 (.204)
L-HDL-CE -.063 (.03) -.144 (.044) -.116 (.051) -.149 (.051) -.134 (.051) -.094 (.047) .519 (.23) .61 (.206)
L-HDL-FC -.082 (.03) -.144 (.045) -.114 (.053) -.128 (.053) -.13 (.051) -.03 (.047) .518 (.181) .59 (.148)
L-HDL-L NA NA -.108 (.05) NA -.132 (.052) NA .457 (.189) .541 (.184)
L-HDL-P -.071 (.028) -.146 (.042) -.111 (.05) -.13 (.049) -.083 (.05) -.1 (.043) .422 (.191) .476 (.155)
L-HDL-PL -.087 (.029) -.161 (.043) -.141 (.051) -.142 (.051) -.105 (.053) -.092 (.044) .443 (.202) .51 (.169)
XL-HDL-C .055 (.046) -.013 (.068) .11 (.066) .064 (.073) .048 (.069) .112 (.068) .474 (.223) .565 (.196)
XL-HDL-CE .064 (.044) .006 (.066) .129 (.066) .08 (.07) .057 (.068) .046 (.075) .426 (.177) .511 (.206)
XL-HDL-FC .009 (.039) -.05 (.059) .066 (.058) -.026 (.067) .102 (.06) .049 (.066) .433 (.16) .609 (.159)
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Method: RAPS/GRAPPLE + All SNPs
Screening GERA GERA GERA GLGC Davis Kettunen GERA + Davis GERA + Davis
Exposure Davis Davis Kettunen Davis Kettunen Davis GLGC + Kettunen GLGC + Kettunen
Outcome CAD UKB UKB UKB UKB UKB CAD + UKB CAD + UKB
Adjusted HDL-C + LDL-C + TG ApoA1 + ApoB + TG
XL-HDL-L NA NA .073 (.055) NA .038 (.058) NA .358 (.154) .481 (.141)
XL-HDL-P .038 (.033) -.022 (.049) .112 (.057) .017 (.056) .083 (.055) .023 (.057) .41 (.139) .39 (.135)
XL-HDL-PL .029 (.031) -.031 (.046) .037 (.05) .005 (.055) .038 (.052) .013 (.046) .343 (.118) .466 (.12)
XL-HDL-TG .092 (.027) .112 (.041) .14 (.047) .135 (.047) .191 (.042) .136 (.039) .147 (.074) .165 (.086)
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Appendix 3.2 Univariable MR results
Appendix 3-Table 3: Mendelian randomization results using genome-wide significant SNPs and inverse variance weighted (IVW) estimator.
Method: IVW + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
VLDL traits
TG .184 (.051) .278 (.076) NA .309 (.074) NA .207 (.064)
VLDL-D .044 (.06) .052 (.09) .038 (.102) .118 (.091) -.083 (.16) -.083 (.138)
XS-VLDL-L NA NA .353 (.08) NA .372 (.083) NA
XS-VLDL-P .162 (.04) .256 (.059) .352 (.081) .273 (.063) .374 (.084) .373 (.095)
XS-VLDL-PL .165 (.046) .262 (.069) .37 (.088) .27 (.075) .443 (.048) .401 (.07)
XS-VLDL-TG .179 (.041) .277 (.061) .362 (.082) .288 (.062) .335 (.076) .314 (.08)
S-VLDL-C .237 (.053) .343 (.08) NA .339 (.083) NA .443 (.116)
S-VLDL-FC .21 (.05) .307 (.076) .344 (.098) .314 (.076) .262 (.122) .397 (.116)
S-VLDL-L NA NA .318 (.095) NA .27 (.106) NA
S-VLDL-P .188 (.049) .274 (.074) .311 (.093) .29 (.072) .266 (.103) .331 (.142)
S-VLDL-PL .198 (.048) .291 (.072) .342 (.091) .3 (.072) .281 (.089) .331 (.125)
S-VLDL-TG .174 (.051) .255 (.076) .296 (.094) .28 (.073) .261 (.102) .262 (.093)
M-VLDL-C .188 (.053) .265 (.08) .305 (.096) .287 (.077) .361 (.078) .32 (.134)
M-VLDL-CE .203 (.051) .285 (.077) .32 (.098) .295 (.076) .264 (.094) .291 (.125)
M-VLDL-FC .165 (.056) .233 (.084) .292 (.098) .27 (.08) .3 (.084) .303 (.104)
M-VLDL-L NA NA .265 (.104) NA .357 (.096) NA
M-VLDL-P .153 (.056) .214 (.085) .276 (.104) .258 (.081) .322 (.092) .268 (.074)
M-VLDL-PL .163 (.054) .23 (.082) .296 (.097) .266 (.078) .302 (.084) .289 (.095)
M-VLDL-TG .14 (.058) .196 (.087) .268 (.107) .247 (.083) .327 (.093) .245 (.091)
L-VLDL-C .177 (.06) .24 (.091) .288 (.106) .286 (.089) .108 (.223) .31 (.084)
L-VLDL-CE .178 (.057) .245 (.087) .262 (.105) .279 (.086) .182 (.187) .299 (.077)
L-VLDL-FC .176 (.063) .242 (.094) .295 (.108) .298 (.091) .321 (.101) .314 (.082)
L-VLDL-L NA NA .291 (.119) NA .125 (.232) NA
L-VLDL-P .164 (.062) .227 (.093) .269 (.108) .275 (.09) .332 (.127) .247 (.076)
L-VLDL-PL .173 (.061) .23 (.092) .308 (.115) .284 (.088) .32 (.127) .302 (.079)
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Method: IVW + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
L-VLDL-TG .149 (.063) .202 (.095) .268 (.118) .267 (.092) .33 (.131) .302 (.08)
XL-VLDL-L NA NA .263 (.123) NA .365 (.286) NA
XL-VLDL-P .149 (.063) .206 (.095) .247 (.122) .268 (.096) .346 (.28) .245 (.077)
XL-VLDL-PL .176 (.067) .243 (.101) .292 (.119) .323 (.101) .333 (.265) .344 (.133)
XL-VLDL-TG .151 (.066) .205 (.1) .241 (.12) .282 (.1) .323 (.272) .249 (.081)
XXL-VLDL-L NA NA .356 (.127) NA -.165 (.425) NA
XXL-VLDL-P .228 (.067) .35 (.099) .372 (.119) .376 (.098) -.12 (.389) .006 (.153)
XXL-VLDL-PL .211 (.07) .31 (.105) .275 (.125) .399 (.107) -.145 (.395) .071 (.191)
XXL-VLDL-TG .221 (.067) .3 (.102) .292 (.126) .415 (.104) .09 (.36) .349 (.303)
IDL/LDL traits
LDL-C .427 (.049) .431 (.054) .409 (.077) .409 (.054) .416 (.099) .422 (.063)
ApoB .506 (.058) .525 (.065) .474 (.093) .473 (.064) .636 (.092) .569 (.071)
LDL-D .217 (.151) .423 (.161) 1.121 (.178) .271 (.143) .309 (.126) .211 (.081)
S-LDL-C .481 (.056) .467 (.063) .445 (.087) .438 (.063) .44 (.128) .436 (.076)
S-LDL-L NA NA .44 (.09) NA .456 (.132) NA
S-LDL-P .501 (.059) .494 (.068) .449 (.093) .472 (.067) .49 (.139) .588 (.097)
M-LDL-C .475 (.057) .457 (.064) .426 (.08) .427 (.064) .418 (.111) .436 (.087)
M-LDL-CE .485 (.058) .47 (.065) .432 (.078) .436 (.064) .43 (.107) .444 (.085)
M-LDL-L NA NA .43 (.08) NA .43 (.11) NA
M-LDL-P .479 (.057) .465 (.064) .437 (.081) .44 (.064) .413 (.122) .439 (.093)
M-LDL-PL .5 (.063) .49 (.071) .437 (.087) .464 (.07) .443 (.132) .497 (.099)
L-LDL-C .449 (.055) .436 (.061) .432 (.076) .411 (.061) .409 (.106) .417 (.076)
L-LDL-CE .464 (.056) .451 (.062) .426 (.075) .422 (.062) .416 (.102) .433 (.077)
L-LDL-FC .425 (.054) .411 (.059) .424 (.074) .393 (.059) .387 (.105) .394 (.078)
L-LDL-L NA NA .427 (.074) NA .407 (.103) NA
L-LDL-P .448 (.054) .442 (.06) .435 (.075) .421 (.059) .413 (.104) .424 (.075)
L-LDL-PL .444 (.056) .438 (.061) .441 (.078) .423 (.061) .42 (.109) .429 (.076)
IDL-C .447 (.055) .455 (.059) .451 (.075) .433 (.06) .439 (.085) .422 (.07)
IDL-FC .429 (.055) .439 (.059) .468 (.075) .414 (.059) .431 (.081) .402 (.074)
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Method: IVW + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
IDL-L NA NA .467 (.075) NA .445 (.085) NA
IDL-P .443 (.055) .467 (.06) .48 (.077) .45 (.059) .446 (.088) .426 (.071)
IDL-PL .429 (.055) .443 (.059) .473 (.078) .427 (.059) .435 (.092) .407 (.069)
IDL-TG .461 (.07) .518 (.076) .625 (.098) .494 (.073) .342 (.085) .34 (.123)
HDL traits
HDL-C -.085 (.044) -.156 (.057) -.146 (.085) -.195 (.06) -.082 (.159) -.015 (.109)
ApoA1 -.072 (.054) -.155 (.071) -.036 (.09) -.194 (.074) .001 (.192) .066 (.158)
HDL-D -.027 (.042) -.071 (.058) -.052 (.073) -.092 (.063) .073 (.098) .074 (.074)
S-HDL-L NA NA -.064 (.148) NA -.033 (.092) NA
S-HDL-P -.117 (.087) -.172 (.116) -.13 (.146) -.298 (.117) -.033 (.09) -.115 (.174)
S-HDL-TG .224 (.063) .317 (.082) .496 (.107) .344 (.085) .334 (.096) .286 (.17)
M-HDL-C -.214 (.062) -.327 (.078) -.48 (.111) -.39 (.079) -.423 (.175) -.39 (.159)
M-HDL-CE -.227 (.062) -.338 (.077) -.497 (.111) -.4 (.078) -.435 (.194) -.341 (.238)
M-HDL-FC -.158 (.065) -.272 (.084) -.341 (.117) -.337 (.085) -.288 (.218) -.278 (.144)
M-HDL-L NA NA -.436 (.125) NA -.514 (.223) NA
M-HDL-P -.172 (.066) -.292 (.087) -.414 (.132) -.361 (.089) -.386 (.307) -.18 (.118)
M-HDL-PL -.161 (.064) -.275 (.085) -.38 (.126) -.345 (.087) -.419 (.301) -.2 (.099)
L-HDL-C -.047 (.044) -.097 (.059) -.124 (.08) -.133 (.063) .022 (.106) .021 (.105)
L-HDL-CE -.049 (.044) -.098 (.059) -.12 (.079) -.137 (.063) .023 (.112) .004 (.106)
L-HDL-FC -.044 (.046) -.094 (.062) -.106 (.082) -.127 (.067) .038 (.103) .017 (.109)
L-HDL-L NA NA -.106 (.077) NA .034 (.102) NA
L-HDL-P -.045 (.043) -.097 (.058) -.102 (.077) -.125 (.063) .009 (.111) .025 (.11)
L-HDL-PL -.054 (.044) -.11 (.06) -.115 (.079) -.14 (.064) .006 (.115) .016 (.115)
XL-HDL-C .03 (.06) -.012 (.084) .014 (.099) -.05 (.088) -.015 (.165) .161 (.101)
XL-HDL-CE .03 (.059) -.009 (.081) .025 (.098) -.042 (.086) -.001 (.166) .221 (.107)
XL-HDL-FC -.003 (.056) -.05 (.076) -.001 (.089) -.077 (.081) .072 (.11) .057 (.092)
XL-HDL-L NA NA .001 (.085) NA -.009 (.138) NA
XL-HDL-P .015 (.049) -.021 (.067) .013 (.088) -.042 (.071) .103 (.1) .135 (.093)
XL-HDL-PL 0 (.047) -.037 (.065) -.026 (.079) -.055 (.069) .081 (.088) .071 (.069)
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Method: IVW + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
XL-HDL-TG .086 (.041) .103 (.059) .14 (.075) .13 (.063) .165 (.043) .126 (.051)
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Appendix 3-Table 4: Mendelian randomization results using genome-wide significant SNPs and the weighted median estimator.
Method: Weighted median + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
VLDL traits
TG .042 (.055) .191 (.072) NA .228 (.069) NA .195 (.077)
VLDL-D -.098 (.052) .039 (.095) .057 (.11) .058 (.093) -.107 (.099) -.052 (.115)
XS-VLDL-L NA NA .312 (.076) NA .393 (.078) NA
XS-VLDL-P .101 (.037) .23 (.052) .303 (.079) .229 (.052) .409 (.08) .253 (.059)
XS-VLDL-PL .096 (.039) .242 (.059) .352 (.087) .228 (.06) .422 (.065) .319 (.062)
XS-VLDL-TG .125 (.041) .266 (.057) .287 (.079) .221 (.056) .361 (.084) .306 (.069)
S-VLDL-C .187 (.059) .232 (.075) NA .256 (.074) NA .303 (.094)
S-VLDL-FC .152 (.057) .207 (.069) .289 (.093) .227 (.069) .316 (.109) .279 (.077)
S-VLDL-L NA NA .282 (.083) NA .306 (.099) NA
S-VLDL-P .131 (.057) .202 (.069) .275 (.085) .221 (.062) .291 (.093) .226 (.078)
S-VLDL-PL .137 (.053) .205 (.067) .283 (.083) .218 (.062) .305 (.092) .263 (.075)
S-VLDL-TG .112 (.057) .204 (.067) .216 (.088) .229 (.064) .267 (.099) .244 (.073)
M-VLDL-C .12 (.058) .2 (.07) .255 (.088) .213 (.066) .303 (.099) .224 (.081)
M-VLDL-CE .144 (.054) .207 (.071) .262 (.087) .207 (.068) .301 (.098) .209 (.072)
M-VLDL-FC .081 (.058) .188 (.074) .221 (.087) .218 (.068) .272 (.102) .231 (.08)
M-VLDL-L NA NA .227 (.095) NA .275 (.109) NA
M-VLDL-P .047 (.06) .191 (.072) .221 (.096) .226 (.069) .31 (.104) .257 (.079)
M-VLDL-PL .103 (.056) .197 (.071) .228 (.089) .217 (.064) .29 (.104) .231 (.078)
M-VLDL-TG -.005 (.06) .199 (.075) .224 (.089) .222 (.068) .318 (.113) .233 (.085)
L-VLDL-C .109 (.068) .2 (.078) .237 (.093) .231 (.075) .242 (.122) .262 (.088)
L-VLDL-CE .147 (.063) .211 (.079) .249 (.09) .253 (.073) .281 (.11) .286 (.081)
L-VLDL-FC .045 (.065) .199 (.085) .225 (.093) .224 (.077) .252 (.125) .228 (.089)
L-VLDL-L NA NA .243 (.102) NA .261 (.122) NA
L-VLDL-P .041 (.064) .209 (.082) .224 (.092) .21 (.079) .289 (.122) .223 (.086)
L-VLDL-PL .08 (.063) .201 (.08) .244 (.101) .224 (.077) .278 (.123) .247 (.092)
L-VLDL-TG -.008 (.061) .215 (.084) .225 (.103) .161 (.077) .286 (.13) .277 (.093)
XL-VLDL-L NA NA .262 (.111) NA NA NA
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Method: Weighted median + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
XL-VLDL-P -.026 (.063) .207 (.091) .289 (.102) .192 (.088) NA .209 (.101)
XL-VLDL-PL -.006 (.067) .197 (.094) .253 (.094) .213 (.088) NA .24 (.101)
XL-VLDL-TG -.026 (.064) .214 (.092) .229 (.102) .191 (.088) NA .212 (.099)
XXL-VLDL-L NA NA .316 (.114) NA -.156 (.22) NA
XXL-VLDL-P .091 (.071) .236 (.089) .267 (.1) .263 (.088) -.104 (.173) .185 (.098)
XXL-VLDL-PL .153 (.082) .283 (.096) .267 (.11) .332 (.095) -.139 (.178) .126 (.124)
XXL-VLDL-TG .126 (.078) .266 (.096) .244 (.108) .339 (.097) .227 (.171) .23 (.123)
IDL/LDL traits
LDL-C .263 (.053) .307 (.066) .274 (.05) .297 (.063) .435 (.072) .431 (.067)
ApoB .365 (.073) .472 (.078) .381 (.063) .375 (.081) .624 (.08) .565 (.094)
LDL-D .306 (.09) .413 (.157) .467 (.163) .271 (.142) .294 (.075) .193 (.06)
S-LDL-C .271 (.058) .342 (.073) .343 (.056) .273 (.068) .498 (.08) .274 (.083)
S-LDL-L NA NA .354 (.061) NA .449 (.081) NA
S-LDL-P .355 (.063) .366 (.078) .397 (.069) .329 (.08) .49 (.089) .581 (.098)
M-LDL-C .283 (.055) .313 (.073) .299 (.05) .244 (.07) .474 (.074) .297 (.074)
M-LDL-CE .27 (.055) .333 (.077) .299 (.051) .255 (.071) .437 (.081) .311 (.077)
M-LDL-L NA NA .303 (.053) NA .432 (.079) NA
M-LDL-P .251 (.057) .32 (.071) .309 (.054) .278 (.07) .409 (.072) .325 (.078)
M-LDL-PL .343 (.063) .337 (.081) .316 (.055) .318 (.078) .457 (.074) .353 (.085)
L-LDL-C .251 (.052) .29 (.067) .303 (.048) .231 (.063) .45 (.075) .309 (.071)
L-LDL-CE .251 (.054) .32 (.068) .293 (.052) .241 (.066) .481 (.074) .322 (.077)
L-LDL-FC .251 (.048) .214 (.061) .301 (.049) .214 (.062) .427 (.068) .289 (.065)
L-LDL-L NA NA .289 (.051) NA .412 (.07) NA
L-LDL-P .281 (.053) .321 (.067) .29 (.053) .244 (.066) .42 (.072) .351 (.072)
L-LDL-PL .286 (.05) .32 (.067) .313 (.052) .298 (.065) .413 (.074) .35 (.076)
IDL-C .283 (.056) .349 (.068) .315 (.053) .313 (.07) .51 (.072) .383 (.068)
IDL-FC .283 (.053) .334 (.066) .337 (.053) .314 (.065) .422 (.067) .367 (.064)
IDL-L NA NA .329 (.056) NA .494 (.069) NA
IDL-P .331 (.06) .44 (.067) .343 (.056) .371 (.069) .463 (.074) .328 (.068)
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Method: Weighted median + Significant SNPs
Selection GERA GERA GERA GLGC Davis Kettunen
Exposure Davis Davis Kettunen Davis Kettunen Davis
Outcome CAD UKB UKB UKB UKB UKB
IDL-PL .265 (.055) .332 (.066) .344 (.056) .316 (.066) .451 (.072) .359 (.066)
IDL-TG .233 (.067) .371 (.086) .605 (.078) .337 (.085) .315 (.082) .215 (.057)
HDL traits
HDL-C -.017 (.04) -.167 (.058) -.17 (.072) -.167 (.058) -.096 (.077) -.085 (.07)
ApoA1 .094 (.049) -.06 (.076) -.069 (.087) -.167 (.07) .005 (.083) -.051 (.121)
HDL-D .079 (.034) .062 (.061) .102 (.064) .088 (.061) .099 (.061) .096 (.058)
S-HDL-L NA NA -.174 (.113) NA NA NA
S-HDL-P -.173 (.069) .018 (.106) -.171 (.109) -.235 (.113) NA -.049 (.108)
S-HDL-TG .157 (.061) .238 (.085) .312 (.105) .228 (.086) .327 (.105) .229 (.076)
M-HDL-C -.169 (.054) -.236 (.082) -.264 (.097) -.241 (.077) -.392 (.098) -.266 (.084)
M-HDL-CE -.166 (.053) -.23 (.08) -.271 (.099) -.238 (.075) -.394 (.103) -.23 (.085)
M-HDL-FC -.166 (.055) -.254 (.086) -.281 (.098) -.282 (.087) -.28 (.102) -.22 (.1)
M-HDL-L NA NA -.296 (.113) NA -.448 (.122) NA
M-HDL-P -.157 (.056) -.199 (.09) -.298 (.112) -.231 (.086) -.291 (.136) -.165 (.131)
M-HDL-PL -.143 (.058) -.183 (.088) -.285 (.108) -.183 (.085) -.321 (.114) -.203 (.12)
L-HDL-C .086 (.037) -.009 (.066) .031 (.083) -.032 (.08) .003 (.09) .006 (.068)
L-HDL-CE .086 (.038) -.011 (.067) .075 (.077) -.037 (.076) .015 (.091) -.006 (.068)
L-HDL-FC .09 (.039) -.005 (.067) .079 (.081) -.019 (.076) .041 (.078) .027 (.074)
L-HDL-L NA NA .074 (.077) NA .068 (.084) NA
L-HDL-P .081 (.036) .046 (.062) .075 (.074) -.01 (.066) .066 (.07) .078 (.064)
L-HDL-PL .084 (.039) 0 (.067) .051 (.082) -.021 (.071) .054 (.075) .074 (.071)
XL-HDL-C .163 (.047) .122 (.091) .136 (.087) .132 (.09) .02 (.098) .161 (.096)
XL-HDL-CE .139 (.044) .106 (.088) .122 (.09) .148 (.085) .038 (.091) .336 (.092)
XL-HDL-FC .135 (.048) .065 (.079) .133 (.081) .027 (.077) .159 (.079) .052 (.086)
XL-HDL-L NA NA .119 (.075) NA .023 (.078) NA
XL-HDL-P .115 (.035) .087 (.07) .12 (.073) .129 (.067) .16 (.071) .15 (.073)
XL-HDL-PL .101 (.037) .064 (.07) .11 (.072) .121 (.069) .141 (.069) .088 (.065)
XL-HDL-TG .074 (.027) .107 (.047) .126 (.051) .118 (.042) .156 (.05) .114 (.045)
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Appendix 3.3 Multivariable MR results
Appendix 3-Table 5: Multivariable Mendelian randomization results (adjusted for HDL-C, LDL-C, and TG).
Trait HDL-C LDL-C TG Subfraction
VLDL traits
VLDL-D -.251 (.052) .29 (.037) .6 (.087) -.588 (.094)
XS-VLDL-L -.086 (.046) .286 (.077) .089 (.099) .132 (.119)
XS-VLDL-P -.083 (.045) .299 (.078) .093 (.106) .118 (.125)
XS-VLDL-PL -.083 (.046) .249 (.098) .112 (.076) .159 (.12)
XS-VLDL-TG -.114 (.046) .463 (.079) .286 (.173) -.157 (.187)
S-VLDL-C -.267 (.084) .754 (.112) 1.033 (.28) -1.035 (.323)
S-VLDL-FC -.195 (.068) .898 (.163) .935 (.26) -1.027 (.337)
S-VLDL-L -.25 (.072) .755 (.112) .876 (.233) -.898 (.28)
S-VLDL-P -.31 (.101) .819 (.157) 1.209 (.4) -1.245 (.463)
S-VLDL-PL -.168 (.051) .673 (.074) .626 (.159) -.613 (.182)
S-VLDL-TG -.499 (.305) .906 (.34) 2.532 (1.57) -2.628 (1.741)
M-VLDL-C -.201 (.068) .808 (.127) 1.472 (.424) -1.433 (.451)
M-VLDL-CE -.168 (.061) .799 (.111) .996 (.249) -1.035 (.293)
M-VLDL-FC -.2 (.072) .658 (.089) 1.469 (.417) -1.412 (.444)
M-VLDL-L -.355 (.139) .602 (.096) 1.787 (.654) -1.878 (.75)
M-VLDL-P -.362 (.124) .569 (.08) 1.889 (.676) -1.974 (.745)
M-VLDL-PL -.332 (.141) .722 (.159) 1.996 (.869) -2.012 (.943)
M-VLDL-TG -.408 (.153) .432 (.061) 1.974 (.772) -2.133 (.879)
L-VLDL-C -.216 (.063) .509 (.046) 1.163 (.254) -1.254 (.297)
L-VLDL-CE -.272 (.072) .465 (.04) 1.038 (.242) -1.081 (.282)
L-VLDL-FC -.144 (.059) .493 (.044) 1.233 (.27) -1.274 (.308)
L-VLDL-L -.228 (.066) .414 (.045) 1.17 (.263) -1.277 (.313)
L-VLDL-P -.115 (.056) .442 (.046) 1.351 (.317) -1.357 (.344)
L-VLDL-PL -.221 (.111) .473 (.07) 2.135 (.948) -2.316 (1.112)
L-VLDL-TG -.196 (.066) .355 (.05) 1.357 (.322) -1.428 (.372)
XL-VLDL-L -.126 (.049) .451 (.04) .896 (.159) -1.069 (.203)
XL-VLDL-P -.127 (.053) .474 (.043) 1.038 (.183) -1.209 (.238)
XL-VLDL-PL -.138 (.055) .5 (.044) 1.052 (.204) -1.214 (.257)
XL-VLDL-TG -.129 (.049) .424 (.04) .944 (.167) -1.071 (.205)
XXL-VLDL-L -.228 (.067) .444 (.043) .978 (.207) -1.355 (.318)
XXL-VLDL-P .063 (.076) .452 (.05) 1.371 (.384) -1.639 (.502)
XXL-VLDL-PL -.185 (.056) .371 (.042) .997 (.185) -1.259 (.262)
XXL-VLDL-TG -.152 (.059) .41 (.04) .966 (.19) -1.202 (.262)
LDL/IDL traits
ApoB -.084 (.046) .8 (.146) .427 (.101) -.532 (.191)
LDL-D -.057 (.042) .367 (.03) .21 (.053) .145 (.061)
S-LDL-C -.062 (.043) .614 (.126) .261 (.062) -.282 (.152)
S-LDL-L -.06 (.044) .584 (.118) .266 (.068) -.251 (.145)
S-LDL-P -.033 (.047) .589 (.119) .29 (.078) -.266 (.151)
M-LDL-C -.082 (.044) .623 (.146) .203 (.054) -.271 (.162)
M-LDL-CE -.074 (.043) .485 (.167) .169 (.059) -.088 (.188)
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M-LDL-L -.071 (.044) .444 (.171) .19 (.063) -.069 (.191)
M-LDL-P -.054 (.044) .539 (.153) .213 (.063) -.179 (.174)
M-LDL-PL -.081 (.045) .747 (.134) .232 (.062) -.407 (.162)
L-LDL-C -.071 (.049) .437 (.242) .167 (.054) -.059 (.261)
L-LDL-CE -.07 (.048) .277 (.301) .149 (.065) .116 (.321)
L-LDL-FC -.112 (.057) .184 (.304) .163 (.053) .223 (.315)
L-LDL-L -.075 (.049) .229 (.26) .146 (.068) .167 (.273)
L-LDL-P -.083 (.046) .33 (.2) .128 (.064) .084 (.213)
L-LDL-PL -.101 (.046) .446 (.177) .155 (.057) -.036 (.195)
IDL-C -.108 (.057) .231 (.215) .128 (.064) .192 (.229)
IDL-FC -.107 (.05) .23 (.147) .123 (.056) .19 (.156)
IDL-L -.1 (.05) .274 (.161) .123 (.069) .148 (.175)
IDL-P -.101 (.047) .269 (.134) .109 (.071) .153 (.148)
IDL-PL -.076 (.048) .25 (.162) .134 (.071) .153 (.18)
IDL-TG -.083 (.046) .314 (.069) .103 (.089) .11 (.103)
HDL traits
ApoA1 .345 (.25) .544 (.081) .334 (.109) -.481 (.271)
HDL-D -.442 (.124) .421 (.033) .111 (.055) .333 (.114)
S-HDL-L -.117 (.046) .488 (.044) .189 (.054) -.312 (.106)
S-HDL-P -.112 (.046) .453 (.035) .225 (.056) -.331 (.095)
S-HDL-TG .002 (.145) .314 (.156) -.007 (.469) .253 (.637)
M-HDL-C .179 (.097) .36 (.038) .147 (.054) -.508 (.165)
M-HDL-CE .167 (.087) .319 (.036) .166 (.055) -.487 (.157)
M-HDL-FC .339 (.141) .436 (.04) .247 (.059) -.649 (.225)
M-HDL-L .27 (.108) .362 (.032) .299 (.063) -.606 (.188)
M-HDL-P .302 (.112) .386 (.033) .371 (.075) -.694 (.204)
M-HDL-PL .311 (.117) .402 (.033) .333 (.07) -.632 (.191)
L-HDL-C -.589 (.211) .469 (.039) .146 (.055) .516 (.213)
L-HDL-CE -.602 (.239) .477 (.042) .137 (.056) .519 (.23)
L-HDL-FC -.573 (.177) .437 (.034) .171 (.054) .518 (.181)
L-HDL-L -.556 (.193) .437 (.034) .142 (.055) .457 (.189)
L-HDL-P -.515 (.198) .417 (.03) .133 (.056) .422 (.191)
L-HDL-PL -.53 (.201) .415 (.034) .152 (.055) .443 (.202)
XL-HDL-C -.447 (.182) .342 (.036) .071 (.079) .474 (.223)
XL-HDL-CE -.425 (.146) .366 (.038) .051 (.069) .426 (.177)
XL-HDL-FC -.459 (.147) .377 (.031) .097 (.062) .433 (.16)
XL-HDL-L -.405 (.146) .364 (.031) .077 (.068) .358 (.154)
XL-HDL-P -.451 (.134) .374 (.03) .078 (.064) .41 (.139)
XL-HDL-PL -.422 (.119) .412 (.033) .115 (.055) .343 (.118)
XL-HDL-TG -.186 (.073) .336 (.035) .045 (.086) .147 (.074)
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Appendix 3-Table 6: Multivariable Mendelian randomization results (adjusted for ApoA1, ApoB, and TG).
Trait ApoA1 ApoB TG Subfraction
VLDL traits
VLDL-D -.227 (.067) .545 (.092) .208 (.139) -.32 (.112)
XS-VLDL-L -.123 (.063) .53 (.163) -.121 (.085) .084 (.141)
XS-VLDL-P -.121 (.064) .553 (.17) -.123 (.088) .061 (.158)
XS-VLDL-PL -.147 (.066) .273 (.138) .028 (.05) .253 (.135)
XS-VLDL-TG -.102 (.06) .762 (.168) .069 (.055) -.248 (.15)
S-VLDL-C -.384 (.141) 1.426 (.354) .606 (.351) -1.265 (.568)
S-VLDL-FC -.188 (.077) 1.001 (.235) .081 (.053) -.489 (.213)
S-VLDL-L -.46 (.146) 1.776 (.417) .7 (.316) -1.629 (.586)
S-VLDL-P -.494 (.159) 1.677 (.386) .825 (.372) -1.644 (.606)
S-VLDL-PL -.262 (.097) 1.41 (.343) .532 (.261) -1.213 (.478)
S-VLDL-TG -.18 (.069) .792 (.121) .078 (.051) -.301 (.108)
M-VLDL-C -.157 (.062) .867 (.132) .085 (.051) -.373 (.118)
M-VLDL-CE -.221 (.069) 1.224 (.223) .47 (.21) -.995 (.338)
M-VLDL-FC -.222 (.074) .902 (.133) .482 (.251) -.799 (.311)
M-VLDL-L -.174 (.065) .76 (.104) .073 (.05) -.298 (.098)
M-VLDL-P -.181 (.065) .764 (.1) .077 (.051) -.312 (.096)
M-VLDL-PL -.159 (.065) .776 (.116) .08 (.051) -.297 (.106)
M-VLDL-TG -.263 (.106) .724 (.094) .547 (.406) -.806 (.455)
L-VLDL-C -.218 (.084) .732 (.101) .352 (.278) -.609 (.337)
L-VLDL-CE -.293 (.079) .781 (.096) .405 (.189) -.673 (.217)
L-VLDL-FC -.197 (.069) .737 (.094) .365 (.25) -.619 (.291)
L-VLDL-L -.194 (.071) .666 (.087) .289 (.234) -.532 (.278)
L-VLDL-P -.184 (.061) .677 (.086) .415 (.217) -.617 (.229)
L-VLDL-PL -.155 (.063) .715 (.095) .075 (.051) -.287 (.104)
L-VLDL-TG -.154 (.062) .67 (.083) .073 (.05) -.252 (.091)
XL-VLDL-L -.186 (.066) .694 (.088) .263 (.19) -.577 (.249)
XL-VLDL-P -.167 (.061) .742 (.088) .075 (.05) -.373 (.109)
XL-VLDL-PL -.191 (.068) .712 (.092) .271 (.197) -.583 (.268)
XL-VLDL-TG -.195 (.068) .666 (.087) .334 (.21) -.603 (.248)
XXL-VLDL-L -.173 (.066) .732 (.098) .088 (.052) -.402 (.144)
XXL-VLDL-P -.071 (.065) .705 (.097) .607 (.321) -1.089 (.449)
XXL-VLDL-PL -.244 (.082) .666 (.091) .414 (.257) -.814 (.344)
XXL-VLDL-TG -.3 (.091) .694 (.095) .627 (.306) -1.075 (.402)
IDL/LDL traits
LDL-C -.119 (.062) .247 (.167) .066 (.054) .319 (.182)
LDL-D -.123 (.06) .544 (.091) -.036 (.087) .119 (.071)
S-LDL-C -.097 (.06) .438 (.216) .044 (.051) .08 (.238)
S-LDL-L -.097 (.063) .503 (.268) .043 (.051) -.005 (.29)
S-LDL-P -.059 (.103) .932 (.597) -.122 (.112) -.362 (.596)
M-LDL-C -.099 (.065) .78 (1.034) -.172 (.425) -.169 (.909)
M-LDL-CE -.157 (.128) -.346 (2.587) .195 (.855) .854 (2.221)
M-LDL-L -.123 (.095) .247 (1.479) -.001 (.445) .32 (1.293)
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M-LDL-P -.134 (.07) .13 (.286) .053 (.052) .432 (.31)
M-LDL-PL -.075 (.077) 1.165 (.868) -.248 (.253) -.566 (.839)
L-LDL-C -.855 (1.68) -5.337 (13.402) 2.405 (5.735) 5.257 (11.72)
L-LDL-CE -.151 (.065) .129 (.193) .061 (.052) .461 (.213)
L-LDL-FC -.397 (.219) -1.139 (1.395) .786 (.711) 1.531 (1.189)
L-LDL-L -.265 (.148) -.854 (1.42) .41 (.51) 1.266 (1.188)
L-LDL-P -.258 (.153) -.607 (1.225) .276 (.402) 1.064 (1.029)
L-LDL-PL -.312 (.187) -.741 (1.411) .39 (.518) 1.227 (1.245)
IDL-C -.3 (.123) -.334 (.616) .276 (.254) .769 (.501)
IDL-FC -.199 (.069) .247 (.118) .044 (.049) .33 (.127)
IDL-L -.215 (.089) .021 (.409) .101 (.15) .444 (.328)
IDL-P -.175 (.075) .214 (.172) .04 (.051) .292 (.173)
IDL-PL -.183 (.07) .159 (.172) .031 (.049) .406 (.184)
IDL-TG -.143 (.075) .565 (.146) -.119 (.087) .047 (.135)
HDL traits
HDL-C -1.513 (1.109) .982 (.314) .27 (.291) 1.446 (1.112)
HDL-D -.457 (.138) .613 (.073) .056 (.049) .296 (.1)
S-HDL-L -.128 (.059) .524 (.062) .067 (.05) -.224 (.087)
S-HDL-P -.132 (.059) .531 (.059) .071 (.05) -.24 (.083)
S-HDL-TG -.11 (.113) .595 (.221) -.057 (.297) -.044 (.466)
M-HDL-C .091 (.084) .459 (.101) -.1 (.083) -.442 (.143)
M-HDL-CE .09 (.078) .291 (.083) .082 (.05) -.413 (.137)
M-HDL-FC .148 (.11) .378 (.063) .066 (.049) -.408 (.166)
M-HDL-L .133 (.091) .491 (.097) -.029 (.086) -.485 (.155)
M-HDL-P .129 (.097) .501 (.097) -.004 (.09) -.472 (.166)
M-HDL-PL .162 (.107) .519 (.096) -.037 (.087) -.486 (.171)
L-HDL-C -.724 (.232) .856 (.132) .032 (.093) .575 (.204)
L-HDL-CE -.761 (.236) .899 (.145) .004 (.084) .61 (.206)
L-HDL-FC -.749 (.174) .842 (.102) .094 (.05) .59 (.148)
L-HDL-L -.717 (.217) .815 (.12) .023 (.089) .541 (.184)
L-HDL-P -.653 (.191) .749 (.104) .057 (.049) .476 (.155)
L-HDL-PL -.679 (.201) .774 (.109) .05 (.049) .51 (.169)
XL-HDL-C -.639 (.194) .692 (.095) -.058 (.086) .565 (.196)
XL-HDL-CE -.576 (.2) .667 (.096) -.077 (.086) .511 (.206)
XL-HDL-FC -.734 (.174) .674 (.073) .094 (.052) .609 (.159)
XL-HDL-L -.652 (.168) .733 (.097) -.06 (.084) .481 (.141)
XL-HDL-P -.52 (.147) .691 (.094) -.075 (.084) .39 (.135)
XL-HDL-PL -.652 (.151) .687 (.076) .079 (.051) .466 (.12)
XL-HDL-TG -.281 (.111) .539 (.09) -.152 (.092) .165 (.086)
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Appendix 3.4 Q-statistics for multivariable Mendelian randomization
Appendix 3-Table 7: Modified Cochran’s Q-statistics (p-values) for the multivariable Mendelian randomization
analyses (adjusted for HDL-C, LDL-C, and TG). DF is short for degrees of freedom.
Trait DF HDL-C LDL-C TG Subfraction
VLDL traits
VLDL-D 432 7640.8 (0) 1918.9 (7.9e-186) 877.6 (1.4e-32) 840.2 (1.6e-28)
XS-VLDL-L 436 7983.9 (0) 1104.9 (1.1e-59) 1935.8 (2.2e-187) 926 (1.9e-37)
XS-VLDL-P 436 7927.8 (0) 1066.6 (1.1e-54) 1814 (4.8e-167) 893.6 (9.6e-34)
XS-VLDL-PL 435 8291.5 (0) 968.1 (1.4e-42) 2771.5 (0) 849.8 (4.3e-29)
XS-VLDL-TG 431 7549.8 (0) 894.4 (1.3e-34) 739.5 (1.3e-18) 682.5 (1.2e-13)
S-VLDL-C 429 8598.1 (0) 652.6 (1.7e-11) 1220.7 (4.6e-77) 541.3 (0.00018)
S-VLDL-FC 434 7861.2 (0) 576 (5.4e-06) 519.4 (0.003) 507.9 (0.0082)
S-VLDL-L 438 7105.3 (0) 626 (8.5e-09) 525.2 (0.0026) 514.3 (0.0069)
S-VLDL-P 438 6686.5 (0) 616.5 (3.6e-08) 515.6 (0.0061) 507.3 (0.012)
S-VLDL-PL 437 7589.1 (0) 702.8 (1e-14) 591.5 (1.1e-06) 555.1 (0.00011)
S-VLDL-TG 437 7658.7 (0) 612.7 (5.3e-08) 498.9 (0.021) 494.5 (0.03)
M-VLDL-C 432 9167.8 (0) 740.8 (1.3e-18) 558.9 (3.5e-05) 551.5 (8.3e-05)
M-VLDL-CE 432 8055.2 (0) 705.9 (1.6e-15) 556.6 (4.6e-05) 539.7 (0.00031)
M-VLDL-FC 436 8272.8 (0) 814.8 (2.7e-25) 528.3 (0.0016) 519.1 (0.0037)
M-VLDL-L 429 7109.2 (0) 1269.2 (5.5e-84) 532.6 (0.00047) 515.9 (0.0025)
M-VLDL-P 436 8260.7 (0) 2059.5 (2.1e-208) 527.5 (0.0017) 516.8 (0.0046)
M-VLDL-PL 435 6849.2 (0) 599.6 (2.6e-07) 496.8 (0.021) 493.5 (0.027)
M-VLDL-TG 436 6123.7 (0) 9854.8 (0) 532.3 (0.0011) 521 (0.0031)
L-VLDL-C 435 8617.2 (0) 8966 (0) 654.7 (4.3e-11) 561.5 (3.9e-05)
L-VLDL-CE 434 6636.6 (0) 11134 (0) 581.6 (2.6e-06) 539.5 (0.00041)
L-VLDL-FC 431 7779.6 (0) 6691 (0) 595.1 (2.5e-07) 562.7 (1.9e-05)
L-VLDL-L 434 8104.9 (0) 5191.4 (0) 560.3 (3.9e-05) 548.6 (0.00015)
L-VLDL-P 435 2308 (5.1e-252) 10360.3 (0) 545.4 (0.00024) 537.9 (0.00054)
L-VLDL-PL 430 8155.4 (0) 1310.8 (8.6e-90) 491.8 (0.021) 489.7 (0.024)
L-VLDL-TG 438 8581.8 (0) 4800.1 (0) 569.1 (2.3e-05) 559.2 (7.5e-05)
XL-VLDL-L 437 8686.8 (0) 8322.2 (0) 674.7 (1.9e-12) 620.2 (1.7e-08)
XL-VLDL-P 431 8550.2 (0) 2459.4 (2e-280) 608.3 (3.6e-08) 588.6 (6.3e-07)
XL-VLDL-PL 431 7478.2 (0) 5042.5 (0) 613.3 (1.7e-08) 591.6 (4.1e-07)
XL-VLDL-TG 433 8237.3 (0) 9628.9 (0) 651.8 (4.6e-11) 618.3 (1.1e-08)
XXL-VLDL-L 439 8476.2 (0) 10436.4 (0) 652.9 (1.3e-10) 570.7 (2.2e-05)
XXL-VLDL-P 437 1291.3 (2.8e-85) 9987.4 (0) 540.3 (0.00053) 529.5 (0.0016)
XXL-VLDL-PL 436 9631.8 (0) 11287.1 (0) 641.6 (4.8e-10) 595.5 (5.3e-07)
XXL-VLDL-TG 429 7809.4 (0) 9476.4 (0) 595.6 (1.7e-07) 564 (1.2e-05)
LDL/IDL traits
ApoB 435 9220.8 (0) 550.1 (0.00014) 1809.7 (1.2e-166) 535.1 (0.00072)
LDL-D 429 2909.2 (0) 3918.8 (0) 2706 (0) 1426.1 (2.9e-107)
S-LDL-C 431 8189.7 (0) 569.8 (7.8e-06) 4880.9 (0) 564.1 (1.6e-05)
S-LDL-L 435 8403.8 (0) 574.4 (7.8e-06) 3931.2 (0) 564.3 (2.7e-05)
S-LDL-P 431 7371.4 (0) 547.1 (0.00012) 3144.7 (0) 537.9 (0.00034)
M-LDL-C 430 9723.7 (0) 570.9 (5.8e-06) 6568.6 (0) 562.9 (1.6e-05)
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Trait DF ApoA1 ApoB TG Subfraction
M-LDL-CE 432 8442.1 (0) 558.3 (3.8e-05) 5773.6 (0) 549.1 (0.00011)
M-LDL-L 430 8801.7 (0) 555.4 (4e-05) 5176.1 (0) 548.2 (9.5e-05)
M-LDL-P 429 8798.9 (0) 541.6 (0.00018) 5049.7 (0) 535.2 (0.00035)
M-LDL-PL 436 7981.7 (0) 573.9 (9.6e-06) 4304.8 (0) 558.9 (6e-05)
L-LDL-C 432 8865.2 (0) 567.7 (1.2e-05) 6179.8 (0) 567 (1.3e-05)
L-LDL-CE 433 8464.3 (0) 558.7 (4.1e-05) 5731.3 (0) 555.6 (5.9e-05)
L-LDL-FC 431 7481.1 (0) 580.6 (1.9e-06) 6760.8 (0) 580.2 (2e-06)
L-LDL-L 433 8486.8 (0) 604.5 (8.9e-08) 5755.8 (0) 601.8 (1.3e-07)
L-LDL-P 434 8310.7 (0) 592.1 (6.3e-07) 5553.3 (0) 584.9 (1.7e-06)
L-LDL-PL 435 8341.4 (0) 588.5 (1.2e-06) 5327.8 (0) 577.4 (5.3e-06)
IDL-C 434 7873.9 (0) 645.5 (1.7e-10) 6336 (0) 642.1 (2.9e-10)
IDL-FC 432 8036 (0) 729.5 (1.4e-17) 6630.5 (0) 725.6 (3e-17)
IDL-L 434 7869.8 (0) 694.5 (2.4e-14) 5198.3 (0) 689 (7e-14)
IDL-P 436 9660.5 (0) 736.7 (9e-18) 5002 (0) 726.6 (7.1e-17)
IDL-PL 431 8432.6 (0) 680.6 (1.7e-13) 5023 (0) 677.4 (3e-13)
IDL-TG 436 7741.2 (0) 1077.5 (4.2e-56) 1992.9 (4.9e-197) 931.6 (4.4e-38)
HDL traits
ApoA1 434 494.1 (0.024) 511.5 (0.006) 932.1 (1.8e-38) 492 (0.028)
HDL-D 438 783.5 (6.6e-22) 8500 (0) 5713.2 (0) 860.1 (9.4e-30)
S-HDL-L 438 3067.3 (0) 4414.6 (0) 3763.2 (0) 882.2 (3.7e-32)
S-HDL-P 438 2592.4 (1.1e-301) 7652.1 (0) 3097.3 (0) 951.1 (4.9e-40)
S-HDL-TG 425 896.9 (6.9e-36) 641.3 (5.2e-11) 540.1 (0.00013) 523 (8e-04)
M-HDL-C 437 957.6 (5.5e-41) 10172.4 (0) 4875.5 (0) 628.3 (4.9e-09)
M-HDL-CE 434 955.3 (3.2e-41) 1383.1 (1.7e-99) 4355.4 (0) 648.3 (1e-10)
M-HDL-FC 432 759.4 (2.4e-20) 2989.1 (0) 3512.2 (0) 538.2 (0.00037)
M-HDL-L 435 914.2 (3e-36) 11535.3 (0) 2327.7 (1.7e-255) 570.3 (1.3e-05)
M-HDL-P 434 997.6 (2.3e-46) 10709.6 (0) 1942.9 (3.2e-189) 561.3 (3.4e-05)
M-HDL-PL 434 977.8 (6.3e-44) 9439.9 (0) 2566 (1.8e-298) 581.3 (2.7e-06)
L-HDL-C 434 580 (3.2e-06) 1257.1 (4.4e-81) 4502.7 (0) 604.3 (1.1e-07)
L-HDL-CE 434 549 (0.00014) 930.2 (3e-38) 5517.2 (0) 557.2 (5.6e-05)
L-HDL-FC 441 627.6 (1.2e-08) 8415.3 (0) 3594 (0) 658.4 (7.9e-11)
L-HDL-L 434 603.6 (1.2e-07) 6743.8 (0) 5314.7 (0) 623.7 (5.7e-09)
L-HDL-P 432 601.1 (1.2e-07) 7769.3 (0) 6024.6 (0) 633.2 (8.6e-10)
L-HDL-PL 434 584.5 (1.8e-06) 9935.5 (0) 3544.3 (0) 611.3 (3.8e-08)
XL-HDL-C 430 732.9 (3.9e-18) 10426.6 (0) 2077.7 (1.4e-213) 686.9 (4e-14)
XL-HDL-CE 430 771.4 (9.3e-22) 8564.4 (0) 2457 (2.2e-280) 711.4 (3.3e-16)
XL-HDL-FC 432 761.8 (1.4e-20) 11265.2 (0) 2549.4 (3.1e-296) 770.9 (1.9e-21)
XL-HDL-L 429 767.6 (1.6e-21) 11490.7 (0) 2355.7 (1.2e-262) 784.6 (3.4e-23)
XL-HDL-P 433 724.9 (4.6e-17) 11372.5 (0) 2539.9 (3.9e-294) 798.5 (4.8e-24)
XL-HDL-PL 443 809.7 (7.8e-24) 10093.1 (0) 5762 (0) 895.4 (7.5e-33)
XL-HDL-TG 432 1849.1 (3.9e-174) 2635.9 (6.5e-312) 2240.8 (2.9e-241) 1267.8 (4.4e-83)
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Appendix 3-Table 8: Modified Cochran’s Q-statistics (p-values) for the multivariable Mendelian randomization
analyses (adjusted for ApoA1, ApoB, and TG). DF is short for degrees of freedom.
Trait DF ApoA1 ApoB TG Subfraction
VLDL traits
VLDL-D 297 1194.1 (9.1e-108) 550 (2.4e-17) 573.7 (8.2e-20) 606.7 (2.1e-23)
XS-VLDL-L 295 1185.1 (6.7e-107) 927 (2e-66) 1151.3 (2.2e-101) 887.9 (1.1e-60)
XS-VLDL-P 295 1194.9 (1.7e-108) 900 (1.9e-62) 895.5 (8.7e-62) 826.7 (6.4e-52)
XS-VLDL-PL 296 1148.5 (1.2e-100) 973.9 (3.2e-73) 2104.2 (1.4e-269) 961.4 (2.5e-71)
XS-VLDL-TG 302 1263.7 (1.1e-117) 757.9 (4.7e-41) 1308.1 (4.4e-125) 976.5 (4.6e-72)
S-VLDL-C 290 988.8 (4.4e-77) 394 (4.5e-05) 459.8 (7.8e-10) 402.6 (1.3e-05)
S-VLDL-FC 296 1092 (1.4e-91) 904 (8.6e-63) 1238.7 (2.1e-115) 1010.4 (8.1e-79)
S-VLDL-L 301 1107.9 (1.1e-92) 412.3 (2.1e-05) 420.8 (5.9e-06) 384.7 (0.00078)
S-VLDL-P 301 1116.6 (4.6e-94) 424.8 (3.3e-06) 401.3 (9.4e-05) 380.6 (0.0013)
S-VLDL-PL 299 1096 (2.3e-91) 428.9 (1.2e-06) 446 (7.1e-08) 432.1 (7.1e-07)
S-VLDL-TG 300 1152.4 (4.3e-100) 908.5 (1.8e-62) 1453.4 (1.8e-150) 1303.1 (7.1e-125)
M-VLDL-C 298 1171.2 (1e-103) 824 (7.3e-51) 1480 (8.9e-156) 1212.5 (1.8e-110)
M-VLDL-CE 298 1185.4 (4.9e-106) 564.4 (1.1e-18) 468.9 (9.2e-10) 431.6 (6.3e-07)
M-VLDL-FC 298 1190.4 (7.4e-107) 899.8 (1.1e-61) 415.2 (8.1e-06) 398.8 (8.4e-05)
M-VLDL-L 298 1144.1 (2.4e-99) 869.8 (2.4e-57) 1381 (1e-138) 1237.4 (1.4e-114)
M-VLDL-P 297 1121.3 (5.7e-96) 821.1 (1.1e-50) 1250.5 (4.6e-117) 1206.7 (8.1e-110)
M-VLDL-PL 298 1149.9 (2.8e-100) 843.2 (1.5e-53) 1391.8 (1.5e-140) 1226.3 (9.8e-113)
M-VLDL-TG 296 1187.4 (5.8e-107) 717.3 (5.8e-37) 366.3 (0.0033) 360.6 (0.006)
L-VLDL-C 295 1196.5 (9.1e-109) 820 (5.6e-51) 462.5 (1.5e-09) 376.9 (0.00088)
L-VLDL-CE 302 1183.1 (1.8e-104) 844.6 (7.4e-53) 541.8 (7.2e-16) 441.7 (2.6e-07)
L-VLDL-FC 295 1172.3 (8.2e-105) 851.6 (1.9e-55) 460.8 (2.1e-09) 406.2 (1.8e-05)
L-VLDL-L 295 1163.6 (2.2e-103) 797 (8.8e-48) 406.5 (1.7e-05) 391.5 (0.00014)
L-VLDL-P 293 1160.2 (2e-103) 809.5 (5.9e-50) 420.2 (1.5e-06) 407.9 (1e-05)
L-VLDL-PL 296 1292 (2.6e-124) 833.4 (1.3e-52) 1216.5 (9.7e-112) 1098.9 (1.1e-92)
L-VLDL-TG 294 1150.8 (1.3e-101) 1213.6 (7e-112) 1262.6 (5.2e-120) 1162.8 (1.5e-103)
XL-VLDL-L 294 1196 (5.4e-109) 829.4 (1.6e-52) 442 (4.9e-08) 423.6 (1.1e-06)
XL-VLDL-P 294 1265.9 (1.4e-120) 1180.9 (1.6e-106) 1202.2 (5.2e-110) 982.1 (5.4e-75)
XL-VLDL-PL 296 1199.1 (6.9e-109) 874.2 (1.9e-58) 421.2 (2.3e-06) 405.6 (2.3e-05)
XL-VLDL-TG 296 1184.3 (1.8e-106) 828.6 (5.9e-52) 430.8 (4.9e-07) 430.1 (5.5e-07)
XXL-VLDL-L 304 1119.2 (1.2e-93) 1041.9 (1.6e-81) 900.9 (2e-60) 699.6 (3.2e-33)
XXL-VLDL-P 303 1148 (1.7e-98) 876.4 (4e-57) 382.2 (0.0013) 366 (0.0076)
XXL-VLDL-PL 303 1203 (2.1e-107) 775.1 (4e-43) 438.1 (5.8e-07) 376.5 (0.0025)
XXL-VLDL-TG 303 1183 (3.7e-104) 881.8 (6.6e-58) 393.7 (0.00034) 372.7 (0.0039)
LDL/IDL traits
LDL-C 293 1198.7 (9.6e-110) 938.8 (1.1e-68) 1060.2 (2.1e-87) 917.6 (1.5e-65)
LDL-D 296 1325.2 (6.7e-130) 747.9 (5.9e-41) 879.1 (3.7e-59) 1163.5 (4.6e-103)
S-LDL-C 296 1195.3 (2.9e-108) 706 (1.6e-35) 1426 (4.1e-147) 686.4 (4.8e-33)
S-LDL-L 296 1054.7 (1.1e-85) 608 (1e-23) 1519.6 (2.2e-163) 586.4 (2.5e-21)
S-LDL-P 297 852.9 (3.6e-55) 438.7 (1.6e-07) 954.7 (4.5e-70) 440.1 (1.3e-07)
M-LDL-C 296 1210.9 (8e-111) 396.2 (8.6e-05) 409 (1.4e-05) 398.9 (6e-05)
M-LDL-CE 295 1204.3 (4.8e-110) 350.8 (0.014) 361.7 (0.0048) 351.3 (0.013)
M-LDL-L 296 1212 (5.3e-111) 370 (0.0022) 392.3 (0.00015) 371.6 (0.0019)
28
Trait DF ApoA1 ApoB TG Subfraction
M-LDL-P 297 1125.4 (1.2e-96) 623.9 (2.3e-25) 911.4 (1.3e-63) 582.4 (9.6e-21)
M-LDL-PL 299 1172.5 (1.2e-103) 399.3 (9.1e-05) 434.9 (4.5e-07) 396.2 (0.00014)
L-LDL-C 300 1174.6 (1.1e-103) 325.5 (0.15) 325.5 (0.15) 325.5 (0.15)
L-LDL-CE 299 1179.5 (9e-105) 769.8 (3e-43) 902.5 (7.7e-62) 743.8 (8.4e-40)
L-LDL-FC 295 1161 (5.8e-103) 322.4 (0.13) 323.2 (0.12) 322.3 (0.13)
L-LDL-L 300 1172.3 (2.6e-103) 336.9 (0.07) 349.6 (0.026) 340.3 (0.055)
L-LDL-P 300 1185.4 (2e-105) 352.1 (0.021) 378.4 (0.0014) 355.4 (0.015)
L-LDL-PL 296 1155.2 (9.8e-102) 343.2 (0.031) 360.1 (0.0063) 344.5 (0.027)
IDL-C 296 1181.7 (4.9e-106) 426.5 (9.8e-07) 427.6 (8.3e-07) 427.7 (8.1e-07)
IDL-FC 298 1096.5 (9.9e-92) 986.9 (1.1e-74) 1075.8 (1.9e-88) 975.4 (6.1e-73)
IDL-L 296 1176.1 (4e-105) 516.7 (3.3e-14) 531 (1.4e-15) 521.4 (1.2e-14)
IDL-P 297 1094.8 (9.5e-92) 910.9 (1.5e-63) 1103.9 (3.5e-93) 890.2 (1.6e-60)
IDL-PL 297 1107.8 (8.3e-94) 798.9 (1.3e-47) 931.6 (1.3e-66) 785.6 (8.6e-46)
IDL-TG 302 1060.8 (5.4e-85) 1052.1 (1.2e-83) 1092.6 (5.6e-90) 1118.3 (4.7e-94)
HDL traits
HDL-C 298 318.7 (0.2) 336.3 (0.063) 329.1 (0.1) 318.6 (0.2)
HDL-D 300 637.4 (1.9e-26) 1156.6 (9.1e-101) 2305.2 (1.3e-305) 1183.8 (3.5e-105)
S-HDL-L 299 1597.7 (4.8e-176) 1222.5 (8.2e-112) 1916.4 (1.5e-233) 1057 (3.1e-85)
S-HDL-P 299 1666.8 (2.5e-188) 1249.4 (2.9e-116) 2146.5 (3.4e-276) 1103.3 (1.6e-92)
S-HDL-TG 299 899 (2.5e-61) 464.9 (2.4e-09) 464.5 (2.6e-09) 457.6 (9.2e-09)
M-HDL-C 299 1145.2 (3.2e-99) 768.2 (4.9e-43) 951.8 (4e-69) 786.8 (1.5e-45)
M-HDL-CE 299 1201.9 (2e-108) 1183.9 (1.7e-105) 2139.7 (6.4e-275) 843.9 (1.9e-53)
M-HDL-FC 298 881.1 (5.6e-59) 1252 (5.5e-117) 1989.1 (2.4e-247) 660.1 (1.8e-29)
M-HDL-L 299 1059 (1.5e-85) 766.4 (8.7e-43) 920.6 (1.7e-64) 672.5 (8.6e-31)
M-HDL-P 298 990.2 (3.5e-75) 760.4 (3.4e-42) 1027.6 (6.2e-81) 613.7 (4.7e-24)
M-HDL-PL 295 929.5 (8.3e-67) 763.9 (2.7e-43) 1057.2 (2.3e-86) 588.3 (1.1e-21)
L-HDL-C 299 579.3 (4.1e-20) 623.2 (5.7e-25) 639.6 (7.3e-27) 617.8 (2.3e-24)
L-HDL-CE 299 612.2 (1e-23) 650.7 (3.6e-28) 690.4 (5.5e-33) 644 (2.2e-27)
L-HDL-FC 308 581.7 (4.4e-19) 857.5 (2.6e-53) 1213.3 (1.4e-107) 915.8 (1.3e-61)
L-HDL-L 299 655.9 (8.7e-29) 747.7 (2.6e-40) 670.7 (1.4e-30) 713.2 (7.5e-36)
L-HDL-P 298 591.3 (1.5e-21) 934 (9.9e-67) 1269.7 (6.2e-120) 956.8 (3.9e-70)
L-HDL-PL 299 580 (3.4e-20) 863.5 (3.3e-56) 1262.4 (2.1e-118) 891.8 (2.8e-60)
XL-HDL-C 298 475.3 (2.7e-10) 734 (1e-38) 976.1 (4.9e-73) 554 (1.3e-17)
XL-HDL-CE 299 472.9 (5.4e-10) 736.9 (6.7e-39) 1117.4 (9e-95) 517.5 (6.5e-14)
XL-HDL-FC 295 527.8 (2.1e-15) 1182.8 (1.6e-106) 2169.4 (3.1e-282) 677.3 (4.3e-32)
XL-HDL-L 298 555.2 (9.6e-18) 701.2 (1.6e-34) 1014 (7.9e-79) 775.3 (3.4e-44)
XL-HDL-P 300 578.9 (6.3e-20) 744.5 (1.1e-39) 1015.5 (1.6e-78) 751.3 (1.4e-40)
XL-HDL-PL 306 604.9 (7.8e-22) 1153.9 (1.4e-98) 1899 (1.5e-227) 909.3 (3.7e-61)
XL-HDL-TG 300 702.2 (2.8e-34) 779.8 (2.2e-44) 1140.8 (3.2e-98) 1399.2 (3.7e-141)
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Appendix 4 Diagnostic plots and the genetic markers
As mentioned above, RAPS is more robust against invalid instruments than other statistical methods for univariable MR, but it still needs the InSIDE
assumption to be approximately satisfied. Zhao et al. [38] described two diagnostic plots RAPS that checks whether there is clear evidence that the InSIDE
assumption is violated. Here we report these plots for HDL-C and M-HDL-P in di↵erent studies. Notice that a lack of evidence to falsify the InSIDE























































































































































































































































Appendix 4-Figure 2: Diagnostic plots for M-HDL-P (selection: Davis; exposure: Kettunen; outcome: UK Biobank).
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Appendix 4.3 Genetic markers for M-HDL-P and S-HDL-P
We can further assess the validity of the InSIDE assumption for M-HDL-P and S-HDL-P but examining the associations of their genetic instruments with
the traditional lipid risk factors and other subfraction traits. We meta-analyzed the summary results in the two lipidome GWAS (Davis and Kettunen)
and obtained SNPs that are associated with S-HDL-P and M-HDL-P (p-value  5 ⇥ 10 8; the results are LD-clumped). The next two Tables show some
information about these genetic markers and their associations with other traits.
Appendix 4-Figure 3 and 4 shows how adjusting for LDL-C and TG changes the e↵ects of the selected SNPs for S-HDL-P and M-HDL-P on CAD. The
adjusted e↵ect on CAD is obtained by original e↵ect on CAD – 0.45 * e↵ect on LDL-C – 0.25 * e↵ect on TG. After the adjustment, the associations of the
genetic variants with CAD generally became closer to the fitted lines that correspond to the estimated e↵ects of S-HDL-P and M-HDL-P.
Appendix 4-Table 1: List of SNPs associated with M-HDL-P.
SNP Chr Gene S-HDL-P M-HDL-P L-HDL-P XL-HDL-P HDL-C LDL-C TG CAD
rs11208004 1 DOCK7 0.039 ** 0.075 *** 0.015 -0.002 0.015 ** 0.050 *** 0.069 *** 0.012
rs4846913 1 GALNT2 0.000 0.061 *** 0.062 *** 0.023 . 0.055 *** -0.006 -0.044 *** -0.025 .
rs2126259 8 LOC157273 0.066 *** 0.082 *** 0.063 ** 0.025 . 0.075 *** 0.063 *** -0.016 . -0.004
rs2083637 8 LPL -0.001 0.058 *** 0.092 *** 0.053 ** 0.105 *** -0.008 -0.108 *** -0.047 **
rs10468017 15 ALDH1A2/LIPC -0.096 *** 0.060 *** 0.209 *** 0.202 *** 0.118 *** 0.002 0.038 *** 0.013
rs247616 16 CETP 0.058 *** 0.121 *** 0.198 *** 0.129 *** 0.243 *** -0.055 *** -0.039 *** -0.044 **
rs1943973 18 LIPG 0.022 0.108 *** 0.104 *** 0.078 *** 0.077 *** 0.024 ** 0.009 -0.016
rs737337 19 DOCK6 0.047 . 0.087 *** 0.081 ** 0.058 * 0.056 *** 0.007 -0.011 -0.038 .
rs769449 19 APOE -0.016 0.078 *** 0.071 *** -0.015 0.064 *** -0.214 *** -0.042 *** -0.085 ***
rs7679 20 PCIF1/PLTP 0.188 *** 0.071 *** -0.129 *** -0.152 *** -0.059 *** 0.009 0.051 *** -0.025 .
Appendix 4-Table 2: List of SNPs associated with S-HDL-P.
SNP Chr Gene S-HDL-P M-HDL-P L-HDL-P XL-HDL-P HDL-C LDL-C TG CAD
rs780094 2 GCKR 0.074 *** 0.034 * -0.04 ** -0.034 * -0.011 . 0.021 ** 0.110 *** 0.005
rs10935473 3 ST3GAL6-AS1 0.052 *** 0.014 -0.029 . -0.031 * -0.009 . 0.003 0.005 -0.007
rs4936363 11 SIK3 0.064 *** 0.046 ** 0.019 0.006 0.034 ** 0.018 . 0.043 *** 0.022
rs2043085 15 ALDH1A2/LIPC 0.092 *** -0.056 *** -0.202 *** -0.197 *** -0.106 *** -0.003 -0.033 *** -0.008
rs1800588 15 ALDH1A2/LIPC 0.106 *** -0.050 ** -0.215 *** -0.212 *** -0.114 *** 0.002 -0.044 *** -0.015
rs289714 16 CETP 0.077 *** 0.122 *** 0.162 *** 0.102 *** 0.214 *** -0.036 *** -0.035 *** -0.012
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Appendix 4-Figure 4: Scatter-plots for M-HDL-P with the e↵ects on CAD adjusted for LDL-C and TG. Red lines correspond the fitted e↵ects of M-HDL-P
in multivariable MR.
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Appendix 4.4 Gene expression
Appendix 4-Table 3: Tissue-specific gene expressions associated with the 4 discovered genetic markers in the gTEX
project.
SNP.Id Type Gene.Symbol Variant.Id P.Value E↵ect Tissue
rs838880 eQTL SCARB1 chr12 124777047 C T b38 1.5E-08 -0.20 Cells - Cultured fibroblasts
rs838880 sQTL SCARB1 chr12 124777047 C T b38 4.1E-06 -0.34 Testis
rs737337 sQTL DOCK6 chr19 11236817 T C b38 3.8E-43 0.99 Artery - Tibial
rs737337 sQTL DOCK6 chr19 11236817 T C b38 6.4E-35 0.93 Adipose - Subcutaneous
rs737337 sQTL DOCK6 chr19 11236817 T C b38 6.4E-35 0.93 Adipose - Subcutaneous
rs737337 sQTL DOCK6 chr19 11236817 T C b38 1.6E-27 0.95 Esophagus - Muscularis
rs737337 sQTL DOCK6 chr19 11236817 T C b38 3.2E-20 1.10 Colon - Sigmoid
rs737337 sQTL DOCK6 chr19 11236817 T C b38 1.1E-17 0.93 Esophagus - Gastroesophageal Junction
rs737337 sQTL DOCK6 chr19 11236817 T C b38 1.8E-09 0.81 Artery - Coronary
rs737337 sQTL DOCK6 chr19 11236817 T C b38 1.2E-07 -0.49 Thyroid
rs737337 sQTL KANK2 chr19 11236817 T C b38 4.4E-07 0.43 Artery - Tibial
rs737337 sQTL KANK2 chr19 11236817 T C b38 3.5E-06 0.55 Heart - Left Ventricle
rs2943641 eQTL IRS1 chr2 226229029 T C b38 1.4E-16 -0.30 Adipose - Subcutaneous
rs2943641 eQTL IRS1 chr2 226229029 T C b38 6.1E-12 -0.23 Adipose - Visceral (Omentum)
rs2943641 eQTL RP11-395N3.2 chr2 226229029 T C b38 3.5E-09 -0.23 Adipose - Subcutaneous
rs2943641 eQTL RP11-395N3.1 chr2 226229029 T C b38 2.1E-07 -0.23 Adipose - Subcutaneous
rs2943641 eQTL RP11-395N3.2 chr2 226229029 T C b38 2.3E-06 -0.19 Adipose - Visceral (Omentum)
rs6065904 eQTL PLTP chr20 45906012 G A b38 4.4E-22 -0.27 Muscle - Skeletal
rs6065904 eQTL PLTP chr20 45906012 G A b38 1.6E-16 -0.27 Adipose - Subcutaneous
rs6065904 eQTL PLTP chr20 45906012 G A b38 1.2E-15 -0.28 Adipose - Visceral (Omentum)
rs6065904 eQTL PLTP chr20 45906012 G A b38 3.2E-15 -0.42 Heart - Atrial Appendage
rs6065904 eQTL PLTP chr20 45906012 G A b38 7.2E-14 -0.25 Artery - Tibial
rs6065904 eQTL PLTP chr20 45906012 G A b38 1.8E-12 -0.27 Nerve - Tibial
rs6065904 eQTL PLTP chr20 45906012 G A b38 7.3E-12 -0.26 Esophagus - Muscularis
rs6065904 eQTL PLTP chr20 45906012 G A b38 2.0E-11 -0.29 Colon - Transverse
rs6065904 eQTL PLTP chr20 45906012 G A b38 4.1E-11 -0.32 Colon - Sigmoid
rs6065904 eQTL PLTP chr20 45906012 G A b38 1.2E-09 -0.26 Artery - Aorta
rs6065904 eQTL PLTP chr20 45906012 G A b38 4.2E-09 -0.29 Heart - Left Ventricle
rs6065904 eQTL PLTP chr20 45906012 G A b38 5.0E-09 -0.22 Thyroid
rs6065904 eQTL PLTP chr20 45906012 G A b38 1.7E-08 -0.29 Stomach
rs6065904 eQTL PLTP chr20 45906012 G A b38 4.3E-08 -0.24 Lung
rs6065904 eQTL NEURL2 chr20 45906012 G A b38 6.6E-08 -0.26 Adipose - Subcutaneous
rs6065904 eQTL PLTP chr20 45906012 G A b38 6.8E-08 -0.33 Liver
rs6065904 eQTL CTSA chr20 45906012 G A b38 4.0E-07 -0.14 Nerve - Tibial
rs6065904 eQTL PLTP chr20 45906012 G A b38 5.3E-07 -0.37 Spleen
rs6065904 eQTL NEURL2 chr20 45906012 G A b38 5.6E-07 -0.26 Adipose - Visceral (Omentum)
rs6065904 eQTL PLTP chr20 45906012 G A b38 8.9E-07 -0.46 Small Intestine - Terminal Ileum
rs6065904 eQTL RP3-337O18.9 chr20 45906012 G A b38 1.8E-06 -0.22 Adipose - Subcutaneous
rs6065904 eQTL WFDC3 chr20 45906012 G A b38 2.9E-06 -0.31 Nerve - Tibial
rs6065904 eQTL DNTTIP1 chr20 45906012 G A b38 3.1E-06 -0.17 Artery - Tibial
rs6065904 eQTL WFDC3 chr20 45906012 G A b38 4.5E-06 -0.27 Skin - Sun Exposed (Lower leg)
rs6065904 eQTL SNX21 chr20 45906012 G A b38 4.8E-06 -0.15 Esophagus - Muscularis
rs6065904 eQTL WFDC3 chr20 45906012 G A b38 8.9E-06 -0.27 Skin - Not Sun Exposed (Suprapubic)
rs6065904 eQTL DNTTIP1 chr20 45906012 G A b38 1.0E-05 -0.14 Nerve - Tibial
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SNP.Id Type Gene.Symbol Variant.Id P.Value E↵ect Tissue
rs6065904 eQTL PLTP chr20 45906012 G A b38 1.1E-05 -0.27 Prostate
rs6065904 eQTL PLTP chr20 45906012 G A b38 1.3E-05 -0.26 Pituitary
rs6065904 eQTL PLTP chr20 45906012 G A b38 1.4E-05 -0.21 Esophagus - Gastroesophageal Junction
rs6065904 eQTL SNX21 chr20 45906012 G A b38 1.5E-05 -0.16 Esophagus - Mucosa
rs6065904 eQTL SNX21 chr20 45906012 G A b38 1.7E-05 -0.23 Colon - Sigmoid
rs6065904 eQTL SNX21 chr20 45906012 G A b38 1.7E-05 -0.17 Thyroid
rs6065904 eQTL PLTP chr20 45906012 G A b38 2.6E-05 -0.21 Breast - Mammary Tissue
rs6065904 eQTL WFDC3 chr20 45906012 G A b38 2.9E-05 -0.23 Artery - Tibial
rs6065904 eQTL NEURL2 chr20 45906012 G A b38 3.2E-05 -0.21 Thyroid
rs6065904 eQTL PLTP chr20 45906012 G A b38 3.7E-05 -0.17 Testis
rs6065904 eQTL CTSA chr20 45906012 G A b38 4.4E-05 -0.11 Skin - Not Sun Exposed (Suprapubic)
rs6065904 eQTL WFDC3 chr20 45906012 G A b38 5.8E-05 -0.23 Muscle - Skeletal
rs6065904 eQTL NEURL2 chr20 45906012 G A b38 8.2E-05 -0.27 Heart - Atrial Appendage
rs6065904 eQTL SNX21 chr20 45906012 G A b38 8.4E-05 -0.17 Artery - Aorta
rs6065904 eQTL NEURL2 chr20 45906012 G A b38 9.5E-05 -0.24 Artery - Aorta
rs6065904 eQTL WFDC3 chr20 45906012 G A b38 9.5E-05 -0.31 Artery - Aorta
rs6065904 eQTL RP3-337O18.9 chr20 45906012 G A b38 9.5E-05 -0.29 Heart - Atrial Appendage
rs6065904 eQTL PLTP chr20 45906012 G A b38 1.2E-04 -0.15 Skin - Sun Exposed (Lower leg)
rs6065904 eQTL WFDC13 chr20 45906012 G A b38 1.5E-04 0.28 Esophagus - Muscularis
rs6065904 eQTL DNTTIP1 chr20 45906012 G A b38 2.1E-04 -0.12 Cells - Cultured fibroblasts
rs6065904 sQTL ZNF335 chr20 45906012 G A b38 3.3E-11 -0.65 Testis
rs6065904 sQTL ACOT8 chr20 45906012 G A b38 1.3E-09 0.58 Heart - Left Ventricle
rs6065904 sQTL PLTP chr20 45906012 G A b38 4.5E-08 -0.32 Whole Blood
rs6065904 sQTL PLTP chr20 45906012 G A b38 4.8E-08 0.53 Spleen
rs6065904 sQTL ACOT8 chr20 45906012 G A b38 1.3E-07 0.42 Esophagus - Mucosa
rs6065904 sQTL ACOT8 chr20 45906012 G A b38 2.6E-07 0.49 Heart - Atrial Appendage
rs6065904 sQTL CTSA chr20 45906012 G A b38 1.0E-06 -0.41 Artery - Aorta
rs6065904 sQTL ACOT8 chr20 45906012 G A b38 1.2E-06 0.33 Nerve - Tibial
rs6065904 sQTL ACOT8 chr20 45906012 G A b38 1.2E-06 0.67 Brain - Spinal cord (cervical c-1)
rs6065904 sQTL TNNC2 chr20 45906012 G A b38 2.1E-06 0.54 Brain - Cerebellum
rs6065904 sQTL ACOT8 chr20 45906012 G A b38 2.1E-06 0.54 Brain - Cerebellum
rs6065904 sQTL WFDC3 chr20 45906012 G A b38 5.5E-06 0.23 Skin - Sun Exposed (Lower leg)
rs6065904 sQTL WFDC3 chr20 45906012 G A b38 9.4E-06 -0.28 Skin - Not Sun Exposed (Suprapubic)
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